FDA Regulation of Cosmetics and Personal Care Products

-name redacted-
Analyst in Public Health and Epidemiology

July 9, 2012
Summary

The 1938 Federal Food, Drug, and Cosmetic Act (FFDCA) granted the Food and Drug Administration (FDA) the authority to regulate cosmetic products and their ingredients. The statutory provisions of the FFDCA that address cosmetics include adulteration and misbranding provisions. In addition to the FFDCA, cosmetics are regulated under the Fair Packaging and Labeling Act (FPLA) and related regulations. The cosmetics provisions were amended by the Color Additive Amendments Act of 1960 and the Poison Prevention Packaging Act, but remain basically the same as the provisions in the 1938 FFDCA.

FDA’s authorities over cosmetic products include some of those applicable to other FDA-regulated products, such as food, drugs, medical devices, and tobacco. For example, FDA has the authority to take certain enforcement actions—such as seizures, injunctions, and criminal penalties—against adulterated or misbranded cosmetics. Additionally, as with drug and food companies, FDA may conduct inspections of cosmetic manufacturers and prohibit imports of cosmetics that violate the FFDCA. The agency also has issued rules restricting the use of ingredients that the agency has determined are poisonous or deleterious.

However, FDA’s authority over cosmetics is less comprehensive than its authority over other FDA-regulated products with regard to registration; testing; premarket notification, clearance, or approval; good manufacturing practices; mandatory risk labeling; adverse event reports; and recalls. For example, FDA does not impose registration requirements on cosmetic manufacturers. Rather, cosmetic manufacturers may decide to comply with voluntary FDA regulations on registration. With the exception of color additives, FDA does not require premarket notification, safety testing, review, or approval of the chemicals used in cosmetic products. Cosmetic manufacturers also are not required to use good manufacturing practices (GMP)—although FDA has released GMP guidelines for cosmetic manufacturers—or required to file ingredient information with, or report adverse reactions to, the agency. Instead, under a voluntary FDA program, cosmetic manufacturers and packagers may report the ingredients used in their product formulations. FDA does not have the authority to require a manufacturer to recall a cosmetic product from the marketplace, although the agency has issued general regulations on voluntary recalls. The agency’s ability to issue regulations on cosmetic products is limited by the agency’s statutory authorities or lack thereof.

As a result, cosmetics are arguably more self-regulated than other FDA-regulated products. The manner in which a cosmetic product could or should be regulated, however, is not always clear. FDA’s guidelines have provided the cosmetic industry with considerable flexibility for product development and claims. The question remains as to whether that flexibility and the extent of government oversight of cosmetic products are still appropriate.
Contents

Introduction...................................................................................................................................... 1
Cosmetics, Drugs, and Combination Products ................................................................................ 2
   Cosmetics .................................................................................................................................. 2
   Drugs ......................................................................................................................................... 3
   Cosmetics Containing Drug Ingredients .................................................................................... 3
Overview of FDA's Authority to Regulate Cosmetics ..................................................................... 5
Adulterated and Misbranded Cosmetics .......................................................................................... 7
   Adulteration ............................................................................................................................... 8
   Misbranding and Mislaveling Claims ........................................................................................ 8
   Enforcement .............................................................................................................................. 9
Voluntary Recalls ........................................................................................................................... 10
Premarket Approval ....................................................................................................................... 11
   Testing and Safety of Cosmetic Ingredients ............................................................................ 13
      Cosmetic Ingredient Review Program .............................................................................. 14
      Consumer Concerns About the Safety of Ingredients ....................................................... 15
Concerns About Specific Ingredients ............................................................................................ 16
   Color Additives ........................................................................................................................ 17
      Coal Tar Hair Dyes ............................................................................................................. 18
   Nanomaterial Ingredients ........................................................................................................ 19
      Nanotechnology Task Force .............................................................................................. 21
      Draft Guidance Regarding the Use of Nanomaterials in FDA-Regulated Products ........ 21
Voluntary Cosmetic Registration Program .................................................................................... 22
Reporting of Adverse Reactions to Cosmetics ............................................................................... 24
Other Concerns with Labeling ....................................................................................................... 25
   “Organic” Labeling Claims on Cosmetic Products ................................................................ 26
   “Not Tested on Animals” Labeling ......................................................................................... 28
   “For Professional Use Only” Labeling .................................................................................... 29
Conclusion ..................................................................................................................................... 30

Appendixes

Appendix. Keratin Hair Treatments, Also Known as “Brazilian Blowouts” .................................. 31

Contacts

Author Contact Information.............................................................................................................. 39
Acknowledgments .......................................................................................................................... 40
Introduction

The U.S. cosmetic, beauty supply, and perfume retail industry consists of approximately 13,000 establishments, with annual revenue of about $10 billion.1 Worldwide, the cosmetics and personal care products industry has more than $250 billion in annual retail sales.2 According to economic census data released in 2009, the U.S. cosmetic industry employs over 86,000 people.3

The cosmetic market includes numerous personal care products that have many uses beyond the facial makeup that one typically thinks of when the term “cosmetics” is used. Industry sales are concentrated in the following areas (percentage of sales by product category): (1) cosmetics, face cream, and perfume—75%; (2) hygienic products including deodorant, shampoo, conditioner, hair color, and shaving products—20%; and (3) small appliances—4%.4 The typical industry consumer is a woman between the ages of 25 to 55, although there appears to be increasing growth in marketing to men and tweens (9- to 12-year-olds).5 Sales of cosmetic and personal care products may be affected by a consumer’s personal income, although the “sales of basic personal items such as soap, shampoo, and shaving products are likely to be less impacted by a soft economy than other product areas viewed by consumers as more discretionary.”6 Prices for cosmetics vary widely, and depend on whether the product is a “prestige,” mass market, or a professional or salon use brand.7

The Food and Drug Administration (FDA) reportedly regulates $62 billion worth of cosmetics.8 FDA’s primary responsibilities for regulating cosmetics include ensuring that cosmetics are not adulterated or misbranded.9 This report describes the differences between cosmetics, drugs, and combination products; provides an overview of the statutory provisions and rules under which FDA regulates cosmetics; and provides an overview of industry self-regulation programs. The report also includes an appendix on keratin hair treatment products, also known as “Brazilian Blowouts.” This report focuses on FDA regulation of cosmetics and does not discuss Federal Trade Commission regulation of advertising of cosmetics nor the regulation of potentially dangerous chemicals or pesticides by other agencies, with the exception of formaldehyde and other agents that may produce or lead to the production of formaldehyde.10

---

4 First Research, supra note 1.
5 First Research, Industry Profile, Personal Care Products Manufacturing, May 16, 2011.
7 First Research, supra note 5.
10 Under the Federal Trade Commission Act, “[i]t shall be unlawful for any person ... to disseminate, or cause to be disseminated, any false advertisement—(1) By United States mails, or in or having an effect upon commerce, by any means, for the purpose of inducing, or which is likely to induce, directly or indirectly the purchase of ... cosmetics; or (continued...
Cosmetics, Drugs, and Combination Products

This section discusses the Federal Food, Drug, and Cosmetic Act (FFDCA) definitions of cosmetics and drugs, and how the FFDCA differentiates between cosmetics and a cosmetic that also meets the statutory definition of a drug. Classification of products is a concern for manufacturers, as cosmetics are not subject to the same approval, regulatory, or registration requirements as drugs. In addition to saving considerable time and expense, this distinction allows manufacturers of products that are only cosmetics and not drugs or combination products, discussed later, to market their products with less regulatory oversight.

Cosmetics

The term “cosmetics” covers a broad range of FDA-regulated products that may be used externally, orificially, and internally. For regulatory purposes, the term “cosmetics” includes products for the eyes, face, nails, hair, skin, and mouth, which may be in the form of products such as makeup, polish, hair dyes and coloring, sunscreens, fragrances, shave gel, oral care and bath products, and products for infants and children. In some settings, cosmetics are known as “personal care products” because of the wide range of products now regulated as cosmetics that are not strictly facial cosmetics. For purposes of this report, “cosmetics” will be used to refer to the entire category of products being discussed.

The FFDCA defines “cosmetics” as “(1) articles intended to be rubbed, poured, sprinkled or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleansing, beautifying, promoting attractiveness, or altering the appearance, and (2) articles intended for use as a component of any such articles; except that the term shall not include soap.” While soap was explicitly exempted from the definition of a cosmetic, and is not defined in the FFDCA, it is defined in FDA regulations. Additionally, coal tar hair dye was provided a limited exemption from the FFDCA’s adulteration provisions.

(...continued)

(2) By any means, for the purpose of inducing, or which is likely to induce, directly or indirectly, the purchase in or having an effect upon commerce, of ... cosmetics.” 15 U.S.C. §52. Additionally, cosmetics are explicitly excluded from the definition of “consumer product” in the Consumer Product Safety Act, which is enforced by the Consumer Product Safety Commission. 15 U.S.C. §2052(a)(5)(H).

12 Examples of cosmetics “that may be introduced into the body are limited, but include mouthwashes, breath fresheners, and vaginal douches.” John E. Bailey, Organization and Priorities of FDA’s Office of Cosmetics and Colors, Cosmetic Regulation in a Competitive Environment, Norman F. Estrin & James M. Akerson, eds., p. 217, 2000.
13 21 C.F.R. §720.4(c)(12).
14 21 U.S.C. §321(i); FFDCA §201(i).
15 The FDA has defined soap in its regulations as applying only to articles for which “(1) [t]he bulk of the nonvolatile matter in the product consists of an alkali salt of fatty acids and the detergent properties of the article are due to the alkali-fatty acid compounds; and (2) [t]he product is labeled, sold, and represented only as soap.” 21 C.F.R. §701.20(a). A product intended not only for cleansing but also for other cosmetic uses such as beautifying, moisturizing, or deodorizing would be regulated by FDA as a cosmetic. A soap-like product may also be a drug, if it is intended to cure, treat, or prevent disease or to affect the structure or any function of the human body. 21 U.S.C. §321(i)(2); FFDCA §201(i)(2).
16 21 U.S.C. §361(a); FFDCA §601(a).
Drugs

The FFDCA defines a “drug” as including articles “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease,” articles that are “intended to affect the structure or any function of the body,” and “articles intended for use as a component” of such drugs.17

Unlike cosmetics and their ingredients (with the exception of color additives), drugs are subject to FDA approval before they can enter interstate commerce. Drugs must either receive the agency’s premarket approval of a new drug application18 or conform to a set of FDA regulations known as a monograph. Monographs govern the manufacture and marketing of over-the-counter (OTC) drugs and specify the conditions under which OTC drugs in a particular category (such as antidiandruff shampoos or antiperspirants) will be considered to be generally recognized as safe and effective.19 Monographs also indicate how OTC drugs must be labeled so they are not deemed to be misbranded.20 Such labeling includes a Drug Facts panel, which provides a listing of the active ingredients in the product as well as the drug’s purposes, uses, and applicable warnings, directions, inactive ingredients, other information, and a telephone number for questions about the product.21

Drug manufacturers must comply with good manufacturing practices (GMP) rules for drugs; failure to follow GMP may cause a drug to be considered adulterated.22 Drug manufacturers also are required to register their facilities, list their drug products with the agency, and report adverse events to FDA.23

Cosmetics Containing Drug Ingredients

While reference to “cosmetic drugs” or “cosmeceuticals” has been used by some proponents in referring to combination cosmetic-drug products, there is not an FDA statutory or regulatory definition for this terminology.24 Cosmeceutical sales are expected to grow faster than the overall cosmetics and toiletries (continued...)
regulations for both cosmetics and drugs. Combination drug and cosmetic products must meet both OTC drug and cosmetic labeling requirements, that is, the drug ingredients must be listed alphabetically as “Active Ingredients,” followed by cosmetic ingredients either listed in a descending order of predominance as “Inactive Ingredients” or listed as “Inactive Ingredients” in particular groups, such as concentrations of greater than one percent of color additives.25

The determination of whether a cosmetic is also a drug, and therefore subject to the additional statutory requirements that apply to drugs, is based on the distributor’s intent or the intended use.26 The intended use of a product may be established in several ways, such as claims on the labeling or in advertising or promotional materials, or through the inclusion of ingredients that will cause the product to be considered a drug because of a known therapeutic use. For example, if a lipstick (a cosmetic) contains sunscreen (a drug), the mere inclusion of the term “sunscreen” in the product’s labeling will cause the product to also be regulated as a drug.27 The text box below provides examples of other combination products and compares cosmetic versus drug classifications.

<table>
<thead>
<tr>
<th>Comparison of Cosmetic and Drug Product Classifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>A suntan product is a cosmetic, but a sunscreen product is a drug.</td>
</tr>
<tr>
<td>A deodorant is a cosmetic, but an antiperspirant is a drug.</td>
</tr>
<tr>
<td>A shampoo is a cosmetic, but an antamdandruf shampoo is a drug.</td>
</tr>
<tr>
<td>A toothpaste is a cosmetic, but an anticavity toothpaste is a drug.</td>
</tr>
<tr>
<td>A skin exfoliant is a cosmetic, but a skin peel is a drug.</td>
</tr>
<tr>
<td>A mouthwash is a cosmetic, but an antigingivitis mouthwash is a drug.</td>
</tr>
<tr>
<td>A hair bulking product is a cosmetic, but a hair growth product is a drug.</td>
</tr>
<tr>
<td>A skin product to hide acne is a cosmetic, but an antiacne product is a drug.</td>
</tr>
<tr>
<td>An antibacterial deodorant soap is a cosmetic, but an antibacterial anti-infective soap is a drug.</td>
</tr>
<tr>
<td>A skin moisturizer is a cosmetic, but a wrinkle remover is a drug.</td>
</tr>
<tr>
<td>A lip softener is a cosmetic, but a product for chapped lips is a drug.</td>
</tr>
</tbody>
</table>

Source: Peter Barton Hutt, "Legal Distinction in USA between Cosmetic and Drug," in Cosmeceuticals and Active Cosmetics: Drugs versus Cosmetics, p. 630 (Peter Elsner & Howard Maibach, eds., 2nd ed. 2005).

(...continued)


25 21 C.F.R. §70.3(a), (f) (setting forth the required designations of ingredients for the labeling of cosmetic products).

26 58 Fed. Reg. 28194, 28204 (May 12, 1993) “When an ingredient can be used for either drug or cosmetic purposes, its regulatory status as a drug or cosmetic, or both, is determined by objective evidence of the distributor’s intent.”

27 21 C.F.R. §700.35 “A product that includes the term ‘sunscreen’ in its labeling … comes within the definition of a drug. … [T]he use of the term ‘sunscreen’ or similar sun protection terminology in a product’s labeling generally causes the product to be subject to regulation as a drug.”
Overview of FDA’s Authority to Regulate Cosmetics

The FFDCA prohibits the adulteration and misbranding of cosmetics and the introduction, receipt, and delivery of adulterated or misbranded cosmetics into interstate commerce. A cosmetic is considered to be adulterated if, among other reasons, it contains a substance which may cause injury to users under the conditions of use prescribed on the product’s labeling or if it contains a filthy, putrid, or decomposed substance. A cosmetic is considered to be misbranded if its labeling is false or misleading, if it does not bear the required labeling information, or if the container is made or filled in a deceptive manner.

Prior to the enactment of the FFDCA in 1938, cosmetics were not regulated by the federal government, but were regulated under a collection of state laws that had been enacted to regulate food and drugs. At that time, several “cosmetics and drugs were made from the same natural materials” and the “laws did not include explicit definitions of the products regulated.”

Following several incidents in which cosmetics were allegedly the cause of serious health problems, as well as industry concerns about states enacting their own laws, provisions were included in FFDCA that prohibited the sale of adulterated or misbranded cosmetics in interstate commerce. The FFDCA also established uniform regulation of FDA-regulated cosmetic products throughout the country.

In addition to the FFDCA, cosmetics are regulated under the Fair Packaging and Labeling Act (FPLA) and related regulations. The FPLA applies to the packaging and labeling of “consumer commodities,” which include cosmetics “customarily produced or distributed for sale through retail sales agencies or instrumentalities for consumption by individuals, or use by individuals for purposes of personal care ... and which [are] usually consumed or expended in the course of such consumption or use.” For the purposes of “for professional use only” labeling, discussed later, the FPLA does not apply to “wholesale or retail distributors of consumer commodities, except to the extent that such persons (1) are engaged in the packaging or labeling of such commodities, or (2) prescribe or specify ... the manner in which such commodities are packaged or labeled.”

---

28 21 U.S.C. §331(a)-(c); FFDCA §301(a)-(c).
30 21 U.S.C. §362; FFDCA §602. In addition to the FFDCA, the Fair Packaging Act and Labeling Act (FPLA) requires cosmetic labels to comply with specific guidelines. If cosmetics are found to be in violation of the FPLA statutory or regulatory provisions, they are considered misbranded for the purposes of the FFDCA. 15 U.S.C. §1456(a); see also U.S. Food and Drug Administration, Key Legal Concepts: “Interstate Commerce,” “Adulterated,” and “Misbranded,” http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/ucm074248.htm.
33 Ibid. at 2.
34 Hutt, supra note 32, p. 5-6; Jacqueline A. Greff, Regulation of Cosmetics That are Also Drugs, 51 Food & Drug L. J. 243, 244 (1996).
35 Hutt, supra note 32, p. 2-3, 6.
The FFDCA statutory provisions that address cosmetics, with the exception of those regarding color additives, have remained basically unchanged since 1938, although the cosmetic industry today encompasses a greater number of products with different uses than those on the market more than seventy years ago. However, concerns of consumer and industry groups today are similar to those expressed prior to the enactment of the FFDCA. Consumer groups have raised concerns about particular ingredients, and states have considered legislating in areas not covered by the FFDCA or federal regulations.39

If a cosmetic that is introduced into, in, or held for sale after shipment in interstate commerce is found to be adulterated or misbranded, FDA may take enforcement actions, such as seeking an injunction (which could prevent a company from making or distributing the violative product), seizing the violative product, or seeking criminal penalties.40 Additionally, FDA has authority to prevent imports of violative cosmetic products from entering the United States.41

FDA’s authority to regulate cosmetics also includes the authority to conduct inspections of cosmetic establishments, without notifying the establishments in advance, as long as the inspections occur “at reasonable times and within reasonable limits and in a reasonable manner.”42 FDA conducts inspections to assure product safety and to evaluate cosmetic products for potential adulteration or misbranding violations.43 The agency may decide to inspect a facility based on consumer or industry complaints, the establishment’s compliance history, or FDA surveillance initiatives.44 The agency may collect samples for examination and analysis during plant and import inspections, and follow up on complaints of adverse events alleged to be caused by a given cosmetic product.45 The agency does not have a required schedule for inspecting cosmetic facilities.

FDA has certain regulations and procedures for cosmetics with which manufacturers voluntarily may choose to comply, even though similar regulations and procedures are mandatory for other FDA-regulated products. For example, FDA has regulations on voluntary facility registration and voluntarily reporting for ingredients used in cosmetic products and adverse reactions to cosmetics.46 In contrast, registration requirements exist for other FDA product manufacturers.47 Additionally, cosmetic manufacturers are not required, as drug manufacturers are, to “file data on ingredients, or report cosmetic-related injuries to FDA.”48 Instead, under a voluntary FDA

42 21 U.S.C. §374(a); FFDCA §704(a).
44 Ibid.
program, cosmetic manufacturers and packagers may report the ingredients used in their product formulations.\(^49\) Furthermore, consumers and cosmetic manufacturers may voluntarily report adverse reactions to cosmetics to FDA. Finally, FDA does not have mandatory recall authority to require a cosmetic manufacturer to recall a product from the marketplace. However, the agency may request a voluntary recall, and FDA has issued general regulations on the conduct of voluntary recalls that outline the agency’s expectations of manufacturers during a recall.\(^50\) While FDA does not have the authority to require compliance with these regulations, FDA may take action against adulterated or misbranded cosmetics.\(^51\)

FDA’s authority over cosmetics is less comprehensive than its authority over other FDA-regulated products with regard to GMP; premarket notification, clearance, or approval; testing; and mandatory risk labeling.\(^52\) As an example, cosmetic producers are not required to use GMP unless their cosmetics are also drugs. FDA has released GMP guidelines for cosmetic manufacturers,\(^53\) and has stated that “[f]ailure to adhere to GMP may result in an adulterated or misbranded product.”\(^54\) With the exception of color additives, FDA does not require premarket notification, safety testing, or premarket review or approval of the chemicals used in cosmetic products.\(^55\) Also, unlike drugs, cosmetic products are not required to meet FDA requirements for safety and effectiveness.\(^56\)

### Adulterated and Misbranded Cosmetics

As previously noted, the FFDCA prohibits the adulteration or misbranding of cosmetics, and the introduction, receipt, and delivery of adulterated or misbranded cosmetics into interstate commerce.\(^57\) If a cosmetic that is introduced into, in, or held for sale after shipment in interstate commerce...

---

\(^{49}\) 21 C.F.R. §720.4.

\(^{50}\) 21 C.F.R. Part 7, Subpart C.

\(^{51}\) FFDCA §301-04.

\(^{52}\) The FDA’s authority over cosmetic products is based primarily on the FFDCA provisions on cosmetics, color additives, and drugs. The agency also has authority under the FPLA for labeling requirements. Other agencies may use their own authorities to regulate certain aspects of cosmetic products, e.g., the Federal Trade Commission regulates the advertising of cosmetics.

\(^{53}\) 21 C.F.R. Parts 210 and 211; FDA, Good Manufacturing Practice (GMP) Guidelines/Inspection Checklist, http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/GoodManufacturingPracticeGMPGuidelinesInspectionChecklist/default.htm. In 1977, the FDA issued a “notice of intent to propose regulations” for the “preservation of cosmetics coming in contact with the eye,” in which the FDA indicated it “expects to promulgate all-inclusive regulations delineating good manufacturing practice for cosmetics at some point, and [the FDA Commissioner] intend[ed] to propose regulations regarding microbial preservation of cosmetics coming in contact with the eye as a first step. 42 Fed. Reg. 54837, 54837, October 11, 1977. The industry trade association—Cosmetic, Toiletry and Fragrance Association, now the Personal Care Products Council—reportedly “filed a petition describing the industry’s preferred cosmetic GMPs,” which were reportedly included by FDA for a time into the agency’s Investigative Operations Manual. Greff, supra note 31, p. 246.


\(^{55}\) 21 U.S.C. §379e; 21 U.S.C. §359. Premarket approval for color additives was established in 1960 with the Color Additive Amendments of 1960. P.L. 86-618. A color additive is basically defined as a substance that, when added or applied to a cosmetic or the body, is capable of imparting coloring. Examples of cosmetics with color additives include lipstick, blush, and eye makeup. 21 U.S.C. §321(t).

\(^{56}\) 21 U.S.C. §355; FFDCA §505.

\(^{57}\) 21 U.S.C. §331(a)-(c); FFDCA §301(a)-(c).
commerce is found to be adulterated or misbranded, FDA may take enforcement actions. The following sections describe the parameters of the adulteration and misbranding of cosmetics.

Adulteration

A cosmetic is deemed adulterated—and potentially may be subject to FDA enforcement actions—if it

- “bears or contains any poisonous or deleterious substance which may render it injurious to users under the conditions of use prescribed in the labeling”;
- consists of “any filthy, putrid, or decomposed substance”;
- was “prepared, packed, or held under insanitary conditions whereby it may have become contaminated” or “rendered injurious to health”;
- is in a container composed of “any poisonous or deleterious substance which may render the contents injurious to health”; or
- contains an unsafe color additive, except for hair dyes.58

FDA has issued rules restricting the use of some ingredients in cosmetic products, such as those that it has determined are poisonous or deleterious, which would cause the cosmetic to be adulterated.59 One example of an adulterated cosmetic is the use of henna for a temporary skin decoration known as mehndi.60 While the color additive used in these products is approved for hair dye, it is not permitted for skin contact.61 Therefore, under FDA regulations, the use of the dye product in mehndi makes the product “adulterated.”62

Misbranding and Mislabling Claims

Cosmetic products that do not comply with FPLA requirements are considered misbranded under FFDCA, if they meet the FPLA’s definition of “consumer commodities,” discussed below.63 Additionally, under FFDCA, cosmetics will be deemed to be misbranded, if

58 21 U.S.C. §361; FFDCA §601; 21 C.F.R. §740.18. “The coal tar hair dye exemption allows coal tar hair dyes, not intended for use on eyelashes or eyebrows, to be marketed to consumers, even if they have been found to be injurious to the user under conditions of use.” Bailey, supra note 12, at 220. The label for coal tar hair dye products must contain the statutorily-required caution statement in order to not be considered to be adulterated, as well as “adequate directions for conducting such preliminary testing,” which are not specified by the FDA, but rather have been set as a self-evaluation patch test with a wait time of 48 hours by the industry-established Cosmetic Ingredient Review (CIR). p. 219-20. If the coal tar hair dye product does not contain that information, the coal tar dye is “subject to regulation as a cosmetic coal additive and must be approved by FDA and listed in the CFR before marketing.” p. 220. In 1952, a congressional committee report recommending the elimination of the coal tar hair dye exemption. Hutt, supra note 32, p. 25. The Government Accountability Office (GAO) also issued a report in the late 1970s recommending the elimination of this exemption. Ibid. p. 27.

59 21 C.F.R. §700.19—Use of methylene chloride as an ingredient of cosmetic products.

60 Henna is “a coloring made from a plant” that is directly applied to the skin “in the body-decorating process known as mehndi.” FDA, Temporary Tattoos & Henna/Mehndi, http://www.fda.gov/Cosmetics/ProductandIngredientSafety/ProductInformation/ucm108569.htm.

61 FDA Import Alert 53-19, October 2, 2009.

62 Ibid.

• the “labeling is false or misleading in any particular”;
• the label lacks required information;\textsuperscript{65}
• required labeling information is not prominently placed with conspicuousness and “in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use”;
• the “container is so made, formed, or filled as to be misleading”;
• use of a color additive does not conform to packaging and labeling requirements; or
• the packaging or labeling violates the regulations issued under the Poison Prevention Packaging Act of 1970.\textsuperscript{66}

Consumer commodity (retail) cosmetic products subject to the FPLA are required to bear a label with the identity of the product and the name and place of business of the manufacturer, packer, or distributor, as well as the net quantity of contents on the label’s principal display panel.\textsuperscript{67} The net quantity of contents information on a package’s label must be declared in a legible type size that is uniform for packages of about the same size.\textsuperscript{68} FDA’s ingredient labeling rules, issued under the authority of the FPLA, require ingredients to be listed on cosmetic products in descending order of predominance.\textsuperscript{69}

**Enforcement**

Consumer organizations and interested persons may submit citizen petitions to FDA asking the agency to determine that a cosmetic is adulterated if it contains a particular deleterious

(...continued)

\textsuperscript{64} 15 U.S.C. §1456(a). However, while the FDA may take enforcement action against consumer commodity products that are considered misbranded because they do not conform to FPLA provisions, the penalty provisions of the FFDCA that could be sought for products deemed misbranded under the FFDCA do not apply to products deemed to be misbranded because they violate the FPLA’s provision on unfair and deceptive packaging and labeling. That FPLA provision makes it unlawful for persons engaged in packing or labeling consumer commodities to distribute, or cause to be distributed, a consumer commodity in a package or with a label that does not meet the FPLA provisions. 15 U.S.C. §1452(a); 15 U.S.C. §1456(a).

\textsuperscript{65} 21 C.F.R. §701.11 (identity labeling); 21 C.F.R. §701.12 (name and place of business of manufacturer, packer, or distributor); 21 C.F.R. §701.13 (declaration of net quantity of contents); 21 C.F.R. 701.3 and 21 C.F.R. §21.66 (designation of ingredients, including active drug ingredients if the cosmetic product is also an over-the-counter drug product); 21 C.F.R. §1.21 (failure to reveal material facts on labeling); 21 C.F.R. Parts 700 and 740 (warning language or requirements for certain cosmetic products).

\textsuperscript{66} 21 U.S.C. §362; FFDCA §602. FDA regulations provide that “[t]he labeling of a cosmetic which contains two or more ingredients may be misleading by reason ... of the designation of such cosmetic in such labeling by a name which includes or suggests the name of one or more but not all such ingredients, even though the names of all such ingredients are stated elsewhere in the labeling.” 21 C.F.R. §701.1(b). FDA regulations also provide that “[a]ny representation in labeling or advertising that creates an impression of official approval because of [the filing of Form FDA 2512, Cosmetic Product Ingredient Statement] will be considered misleading.” 21 C.F.R. §720.9.

\textsuperscript{67} The principal display panel is “that part of a label that is most likely to be displayed, presented, shown, or examined under normal and customary conditions of display for retail sale.” 15 U.S.C. §1459(f); 21 C.F.R. §701.10.

\textsuperscript{68} 15 U.S.C. §1453(a)(3); 21 C.F.R. §701.2—Form of stating labeling requirements.

\textsuperscript{69} 15 U.S.C. §1454(c)(3); 21 C.F.R. §701.3(a). However, the FDA’s regulation does “not require the declaration of incidental ingredients that are present in a cosmetic at insignificant levels and that have no technical or functional effect in the cosmetic” such as processing aids. 21 C.F.R. §701.3(l).
FDA Regulation of Cosmetics and Personal Care Products

substance. For example, in 1996, FDA denied such a petition after conducting a review of the cosmetic ingredient urocanic acid and “conclud[ing] that the scientific evidence did not establish urocanic acid to be a deleterious substance.”

If a cosmetic is deemed adulterated or misbranded, FDA may take enforcement actions. Enforcement actions may include seeking an injunction (which could prevent a company from making or distributing the violative product), seizing the violative product, or seeking criminal penalties. Additionally, a cosmetic company may be subject to a product liability lawsuit for a product that could be deemed to be adulterated, misbranded, or that lacks adequate warning statements.

Voluntary Recalls

FDA does not have authority to order a mandatory recall of a cosmetic product. In contrast, the agency has the authority to order recalls of food, infant formula, medical devices, human tissue products, and tobacco products. Even though FDA may not order a mandatory recall, FDA may request that a company voluntarily recall cosmetic products. Manufacturers or distributors may undertake voluntary recalls to remove violative products from the market that are hazardous to health, defective, or grossly deceptive, and “against which the agency would initiate legal action.” If a manufacturer or distributor is unwilling to remove dangerous products from the market without FDA’s written request to do so, the agency may issue a request for a product recall.

The agency monitors a firm that conducts a product recall, and the agency may take an active role in monitoring a recall by reviewing the firm’s status reports and conducting its own audit checks to verify the recall’s effectiveness. FDA evaluates the health hazard presented by the product and assigns a classification to indicate the degree of hazard posed by the product under recall, whether it is a cosmetic or another FDA-regulated product (see text box). Either FDA or the

---

70 Bailey, supra note 12, p. 218.
71 Ibid.
75 FFDCA §412(f).
76 FFDCA §518(e).
78 FFDCA §908(c).
80 21 C.F.R. §7.3(g); 21 C.F.R. §7.40(a).
81 21 C.F.R. §7.45.
82 21 C.F.R. §7.53.
83 21 C.F.R. §7.41.
cosmetic company will issue public notification of the recall. The firm is responsible for the disposition of the recalled product, whether it is destroyed or brought into compliance.

### Classification of Recall by Degree of Health Hazard

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class I</strong></td>
<td>A situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause adverse health consequences or death.</td>
</tr>
<tr>
<td><strong>Class II</strong></td>
<td>A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.</td>
</tr>
<tr>
<td><strong>Class III</strong></td>
<td>A situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.</td>
</tr>
</tbody>
</table>

**Source:** 21 C.F.R. §7.3(m).

### Premarket Approval

In contrast to FDA’s authority over drugs and some devices, FDA does not have the authority to require premarket approval of cosmetics or their ingredients, except for color additives. Because there are no statutory requirements for premarket approval of cosmetic ingredients, manufacturers are responsible for substantiating the safety of their products and ingredients before the products are marketed. Failure to adequately substantiate the safety prior to marketing causes the product to be considered misbranded, unless it bears a warning label that states: “The safety of this product has not been determined.” However, because that warning label seems to be rarely used, consumers may be under the impression that cosmetics have been demonstrated to be safe. The Government Accountability Office (GAO) has noted that FDA’s regulation requiring warning labels “cannot be effectively enforced because FDA does not have the authority to require cosmetic manufacturers to test their products for safety or make their test results available to FDA.”

---

84 21 C.F.R. §§7.42(b)(2), 7.50.
87 FDA, FDA Authority Over Cosmetics, supra note 86. The FDA has said that “the safety of a product can be adequately substantiated through (a) reliance on already available toxicological test data on individual ingredients and on product formulations that are similar in composition to the particular cosmetic, and (b) performance of any additional toxicological and other tests that are appropriate in light of such existing data and information. Although satisfactory toxicological data may exist for each ingredient of a cosmetic, it will still be necessary to conduct some toxicological testing with the complete formulation to assure adequately the safety of the finished cosmetic.” FDA, Cosmetic Products: Warning Statements/Package Labels, 40 Fed. Reg. 8912, 8916, March 3, 1975; FDA, Cosmetics, Product Testing, http://www.fda.gov/Cosmetics/ProductandIngredientSafety/ProductTesting/default.htm.
88 21 C.F.R. §740.10.
89 Bailey, supra note 12, p. 218, stating that “[n]o product has ever been encountered in retail commerce that bears the warning statement specified in 21 CFR 740.10.”
90 The Food and Drug Administration’s Regulation of Cosmetics: Before the Subcomm. on Oversight and Investigations of the House Comm. on Interstate and Foreign Commerce, p. 4, February 3, 1978, statement of Gregory J. Ahart, Director, Human Resources Division, GAO.
FDA, however, has restricted the use of certain ingredients in cosmetics or required warning statements on the labels of certain types of cosmetics (see textbox below). For example, FDA issued a rule banning the use of methylene chloride in cosmetics after concluding “that methylene chloride is a poisonous or deleterious substance that may render cosmetic products injurious to users,” due to the potential cancer risks of exposure to the substance.91 If a cosmetic were to contain methylene chloride, it would be considered adulterated, and FDA could take an enforcement action.

Except for color additives and those cosmetic ingredients that are prohibited or restricted for use by a specific regulation, any ingredient used in the formulations of cosmetics is allowed, provided that the safety of the ingredient has been adequately substantiated, it is properly labeled, and its use does not cause the product to be adulterated or misbranded under the law. FDA’s guidance document on inspections of cosmetic product manufacturers discusses several other ingredients that investigators should document if they are used in cosmetic products.92

---

91 54 Fed. Reg. 27328, 27340, June 29, 1989; 21 C.F.R. §700.19(b), “Any cosmetic product that contains methylene chloride as an ingredient is deemed adulterated and is subject to regulatory action under sections 301 and 601(a) of the [FFDCA].”

92 For example, acetyl ethyl tetramethyl tetralin (AETT) was “voluntarily discontinued” by the fragrance industry in 1978 after it “was found to cause serious neurotoxic disorders and discoloration of internal organs” in a 1977 toxicity study of rats. FDA, Cosmetic Product Manufacturers (2/95), Guide to Inspections of Cosmetic Product Manufacturers, http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074952.htm.
FDA has either restricted the use of the following ingredients in cosmetics or required warning statements on the labels of certain types of cosmetics.

21 C.F.R. §250.250 Hexachlorophene
21 C.F.R. §700.11 Cosmetics containing bithionol
21 C.F.R. §700.13 Use of mercury compounds in cosmetics including use as skinbleaching agents in cosmetic preparations also regarded as drugs
21 C.F.R. §700.14 Use of vinyl chloride as an ingredient including propellant of cosmetic aerosol products
21 C.F.R. §700.15 Use of certain halogenated salicylanilides as ingredients in cosmetic products
21 C.F.R. §700.16 Use of aerosol cosmetic products containing zirconium
21 C.F.R. §700.18 Use of chloroform as an ingredient in cosmetic products
21 C.F.R. §700.19 Use of methylene chloride as an ingredient of cosmetic products
21 C.F.R. §700.23 Chlorofluorocarbon propellants
21 C.F.R. §700.27 Use of prohibited cattle materials in cosmetic products
21 C.F.R. §700.35 Cosmetics containing sunscreen ingredients
21 C.F.R. §740.10 Labeling of cosmetic products for which adequate substantiation of safety has not been obtained
21 C.F.R. §740.11 Cosmetics in self-pressurized containers
21 C.F.R. §740.12 Feminine deodorant sprays
21 C.F.R. §740.17 Foaming detergent bath products
21 C.F.R. §740.19 Suntanning preparations

Source: Title 21, Code of Federal Regulations.

Testing and Safety of Cosmetic Ingredients

FDA has advised cosmetic firms to employ appropriate and effective testing to substantiate the safety of their products. However, the FFDCA does not specify how cosmetic products and their ingredients are to be tested. As mentioned earlier, manufacturers are responsible for substantiating the safety of both the ingredients and finished cosmetic products prior to marketing.

Traditional testing of cosmetic ingredients has used animal models to evaluate the safety of the ingredients on the human body. The tests used historically include measures of skin irritancy, eye irritation, allergic reactions, and toxicity caused by various ingredients used in the manufacture of

---

93 21 C.F.R. §740.10.
cosmetics on several different animals, including rabbits, mice, rats, and guinea pigs.96 Animal testing is allowed to be used to establish product safety.97

While concerns about the safety of cosmetics have been raised over the years, animal rights advocates have sought an end to animal testing.98 FDA has said that it follows applicable laws on animal testing, such as the Animal Welfare Act.99 Additionally, the agency has outlined its support for alternatives to whole-animal testing:

FDA supports and adheres to the provisions of applicable laws, regulations, and policies governing animal testing, including the Animal Welfare Act and the Public Health Service Policy of Humane Care and Use of Laboratory Animals. Moreover, in all cases where animal testing is used, FDA advocates that research and testing derive the maximum amount of useful scientific information from the minimum number of animals and employ the most humane methods available within the limits of scientific capability ... We also believe that prior to use of animals, consideration should be given to the use of scientifically valid alternative methods to whole-animal testing. ...

FDA supports the development and use of alternatives to whole-animal testing as well as adherence to the most humane methods available within the limits of scientific capability when animals are used for testing the safety of cosmetic products. We will continue to be a strong advocate of methodologies for the refinement, reduction, and replacement of animal tests with alternative methodologies that do not employ the use of animals.100

Cosmetic Ingredient Review Program

Although the FFDCA does not specify how ingredients in cosmetic products are to be tested, the cosmetic industry’s trade association—the Personal Care Products Council (PCPC)—has established a Cosmetic Ingredient Review (CIR) program to review the safety of cosmetic product ingredients, based on published and unpublished data on individual ingredients. The purpose of the CIR program “is to determine those cosmetic ingredients for which there is a reasonable certainty in the judgment of competent scientists that the ingredient is safe under its conditions of use.”101

Under the CIR program, an expert panel reviews cosmetic ingredients based on an annual priority list of ingredients currently used in commercially available cosmetics, which is based upon “the number of different products in which an ingredient is used” as obtained from the Voluntary

100 FDA, Animal Testing, supra note 97.
Cosmetic Registration Program\textsuperscript{102} as well as “toxicological considerations.”\textsuperscript{103} Panelists analyze data and determine whether an ingredient is (1) safe for the uses and concentrations in the safety assessment; (2) unsafe and therefore unsuitable for use in cosmetics; (3) safe, with qualifications, as in it can be used under certain conditions; or (4) an ingredient for which data are insufficient.\textsuperscript{104} Although CIR’s ingredient findings are published, the cosmetic industry is not required to follow CIR findings.\textsuperscript{105}

As of February 2012, CIR has determined 1,398 ingredients “safe as used”;\textsuperscript{106} 987 ingredients safe with qualifications;\textsuperscript{107} 43 ingredients with insufficient data to support safety;\textsuperscript{108} and 11 ingredients “unsafe for use in cosmetic products.”\textsuperscript{109}

In addition, the Research Institute for Fragrance Materials (RIFM) “conducts a companion program to review the safety of fragrance ingredients” that includes a “systematic evaluation of fragrance ingredients used in cosmetic products.”\textsuperscript{110}

### Consumer Concerns About the Safety of Ingredients

In 2004, concerns raised about the safety of some cosmetics led to the creation of a national coalition of environmental, health, labor, consumer, and women’s groups called the Campaign for Safe Cosmetics.\textsuperscript{111} The Campaign is concerned about what it believes to be a growing body of evidence that suggests a connection between certain chemicals and long-term health effects such as cancer and reproductive problems. Of particular concern are the health effects of nitrosamines,\textsuperscript{112} lead and other heavy metals,\textsuperscript{113} parabens,\textsuperscript{114} phthalates,\textsuperscript{115} hydroquinone,\textsuperscript{116} and 1,4-dioxane.\textsuperscript{117}

\textsuperscript{102} The Voluntary Cosmetic Registration Program is discussed in greater detail \textit{infra}.
\textsuperscript{106} CIR, Cosmetic ingredients found safe as used (through February 2012), available at http://www.cir-safety.org/supplementaldoc/safe-used.
\textsuperscript{107} CIR, Cosmetic ingredients found safe, with qualifications (through February 2012), http://www.cir-safety.org/supplementaldoc/safe-qualifications.
\textsuperscript{108} CIR, Cosmetic ingredients with insufficient data to support safety (through February 2012), http://www.cir-safety.org/cir-findings.
\textsuperscript{109} CIR, Ingredients found unsafe for use in cosmetics (through February 2012), http://www.cir-safety.org/supplementaldoc/unsafe-ingredients.
\textsuperscript{110} RIFM, a nonprofit corporation, works in part to “encourage uniform safety standards related to the use of fragrance ingredients.” The corporation reportedly has the world’s largest database of flavor and fragrance materials, with more than 5,000 materials, RIFM, About Us, http://www.rifm.org/about.php.
\textsuperscript{111} The Campaign for Safe Cosmetics, http://www.safecosmetics.org/.
\textsuperscript{112} “Cosmetics containing as ingredients amines and amino derivatives ... may form nitrosamines, if they also contain an ingredient which acts as a nitrosating agent ... Many nitrosamines have been determined to cause cancer in laboratory animals. They have also been shown to penetrate the skin.” FDA expressed its concern about the contamination of cosmetics with nitrosamines in a Federal Register notice dated April 10, 1979, which stated that cosmetics containing nitrosamines may be considered adulterated and subject to enforcement action. FDA, Cosmetic Product Manufacturers: Guide to Inspections of Cosmetic Product Manufacturers, http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074952.htm.
\textsuperscript{113} “FDA has not set limits for contaminants, such as lead, in cosmetics. However, FDA does set specifications for (continued...)
Beginning in 2004, the Campaign asked cosmetic companies to sign the Compact for Safe Cosmetics, which was a voluntary pledge by companies to take steps including disclosure of all ingredients, publication of product information in an ingredient database, and substantiation of “the safety of all products and ingredients with publicly available data.”118 More than 1,500 companies have signed the pledge to remove hazardous chemicals and replace them with safe alternatives within three years.119

The Campaign for Safe Cosmetics has also issued reports, which cover subjects such as contaminants in children’s bath and personal care products.120 The Environmental Working Group—a member of the Campaign for Safe Cosmetics—maintains a database of cosmetic product ingredients and related safety information.121

Concerns About Specific Ingredients

Some ingredients used in cosmetic products have received particular attention as a result of concerns about their potential health risk. For example, questions have been raised about the accuracy of ingredient statements and the adequacy of safety warnings on product labels for keratin hair treatment products122 containing formaldehyde.123 Concerns have also arisen

(...continued)

impurities, such as lead, for color additives used in cosmetics.” FDA, Lipstick and Lead: Questions and Answers, http://www.fda.gov/Cosmetics/ProductandIngredientSafety/ProductInformation/ucm137224.htm.


115 Phthalates are “a group of chemicals used in hundreds of products, such as ... nail polish, hair sprays, soaps, and shampoos.” FDA, Phthalates and Cosmetic Products, http://www.fda.gov/Cosmetics/ProductandIngredientSafety/SelectedCosmeticIngredients/ucm128250.htm. Also CRS Report RL34572, Phthalates in Plastics and Possible Human Health Effects, by (name redacted) and (name redacted).

116 “Hydroquinone is a skin bleaching ingredient used to lighten areas of darkened skin.” FDA, Hydroquinone Studies Under The National Toxicology Program (NTP), http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm203112.htm.

117 “The compound 1,4-dioxane is a contaminant that may be present in extremely small amounts in some cosmetics. It forms as a byproduct during the manufacturing process of certain cosmetic ingredients. ... However, 1,4-dioxane itself is not used as a cosmetic ingredient.” FDA, 1,4-Dioxane, http://www.fda.gov/Cosmetics/ProductandIngredientSafety/PotentialContaminants/ucm101566.htm.


121 Environmental Working Group, Skin Deep Database, About the Environmental Working Group, http://www.ewg.org/about.


123 See the Appendix for a more detailed discussion of keratin hair treatment products containing formaldehyde.
regarding the use of coal tar hair dyes as color additives and nanomaterial ingredients, which are discussed more below.

**Color Additives**

As previously discussed, FDA does not require premarket approval of cosmetic ingredients, except for color additives. FDA regulates color additives—such as FD&C Blue No. 1—differently than other cosmetic ingredients and differently for use in cosmetics than for use in food, drugs, or medical devices. Color additives include any dye, pigment, or substance that may impart a color when added to a food, drug, cosmetic, or the human body, and must be listed in a regulation before they are allowed to be used. A cosmetic that contains a color additive that does not comply with the applicable FDA regulation will cause the cosmetic product to be considered to be adulterated.

Additionally, some color additives must be certified by FDA before they may be used. Failure to certify a color additive may cause the entire cosmetic product in which it is used to be deemed to be adulterated. Batches of color additives are either subject to, or exempt from, certification by FDA. The color additives that are subject to certification “are derived primarily from petroleum,” while color additives exempt from certification “are obtained primarily from mineral, plant, or animal sources.” Regardless of whether a color additive is subject to certification, all

---


125 21 C.F.R. §70.3(f); see also FFDCA §201(t)(1) The term “color additive” means a material which—(A) is a dye, pigment, or other substance made by a process of synthesis or similar artifice, or extracted, isolated, or otherwise derived, with or without intermediate or final change of identity, from a vegetable, animal, mineral, or other source, and (B) when added or applied to a food, drug, or cosmetic, or to the human body or any part thereof, is capable (alone or through reaction with other substance) of imparting color thereto; except that such term does not include any material which the Secretary, by regulation, determines is used (or intended to be used) solely for a purpose or purposes other than coloring. The term “color” includes black, white, and intermediate grays.

126 21 U.S.C. §379e(a); FFDCA §721(a).

127 21 U.S.C. §379e(a); FFDCA §721(a); 21 U.S.C. §361(e); FFDCA §601(e).

128 “In the certification procedure, a representative sample of a new batch of color additive, accompanied by a ‘request for certification’ that provides information about the batch, must be submitted to FDA’s Office of Cosmetics and Colors. FDA personnel perform chemical and other analyses of the representative sample and, providing the sample satisfies all certification requirements, issue a certification lot number for the batch.” 76 Fed. Reg. 10371, 10372 (February 24, 2011); 21 C.F.R. Part 80.

129 21 U.S.C. §379e(a); FFDCA §721(a); 21 C.F.R. §71.25.

130 21 U.S.C. §379e(c); FFDCA §721(c); 21 C.F.R. Part 73, Subpart C, Listing of Color Additives Exempt from Certification; 21 C.F.R. Part 74, Subpart C, Listing of Color Additives Subject to Certification; see also FDA, Color Additives Permitted for Use in Cosmetics: Table, http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/VoluntaryCosmeticsRegistrationProgramVCRP/OnlineRegistration/ucm109084.htm.

131 Ibid.
color additives must be approved as “safe-for-use” prior to being listed and therefore able to be used in cosmetics.\footnote{132}

In addition to being subject to certification by FDA, color additives must be used according to FDA regulations that prescribe “the conditions under which such additive may be safely used.”\footnote{133} For example, the color additive FD&C Red No. 4 must meet the requirements of 21 C.F.R. §74.1304(a)(1) and (b), which discuss identity (the composition and specifications the color additive must meet, such as the maximum amounts of particular impurities that the color additive can contain) and restrict its use to “externally applied drugs and cosmetics.”\footnote{134} Under FDA regulations, the external application of cosmetics does not include “the lips or any body surface covered by mucous membrane,” and therefore FDA regulations prohibit the use of certain colors in cosmetics such as lipsticks.\footnote{135} As additional examples, FDA has specific regulations for an approved glow-in-the-dark color additive and for fluorescent color additives (some of which are approved for use in cosmetics) and for liquid crystal color additives (which are unapproved color additives and, therefore, are not approved for use in cosmetics).\footnote{136} FDA regulations also contain restrictions on color additives for use in the eye area, in injections (such as for tattoos or permanent makeup), and in surgical sutures, including that the listing or certification of the color additive must allow that specific use.\footnote{137}

### Coal Tar Hair Dyes

Coal tar dyes have been a particularly controversial group of color additives, due to their potential health risk. Coal tar dyes are “synthetic-organic” colors, most of which are “made from petroleum.”\footnote{138} These dyes, “which deposit and adhere to the hair shaft,” “are either listed and certified color additives or dyes for which approval has not been sought.”\footnote{139} They were specifically exempted from the FFDCA adulteration and other color additive provisions for products that are intended to dye hair.\footnote{140}

FDA, GAO, policymakers, and consumer groups have questioned whether the FFDCA exemption for coal tar hair dyes should be repealed because of potential health hazards.\footnote{141} On several

---

\footnote{132}{The FDA’s “safe-for-use” principle “require[s] the presentation of all needed scientific data in support of a proposed listing to assure that each listed color additive will be safe for its intended use in or on ... cosmetics.” 21 C.F.R. §70.42. In this context, “safe” means “that there is convincing evidence that establishes with reasonable certainty that no harm will result from the intended use of the color additive.” 21 C.F.R. §70.3(i).}
\footnote{133}{21 U.S.C. §379e(a); FFDCA §721(a).}
\footnote{134}{21 C.F.R. §82.304.}
\footnote{135}{21 C.F.R. §70.3(v); FDA, Color Additives and Cosmetics, http://www.fda.gov/ForIndustry/ColorAdditives/ColorAdditivesinSpecificProducts/InCosmetics/ucm110032.htm}
\footnote{136}{E.g., 21 C.F.R. §73.2995—Luminescent zinc sulfide; FDA, Color Additives and Cosmetics, supra note 121.}
\footnote{137}{21 C.F.R. §70.5. The FDA notes that it has not approved any color additive for skin injections such as tattoos or permanent makeup. FDA, Color Additives and Cosmetics, supra note 121. Additionally, color additives may be required to be labeled as “Do not use for coloring drugs for injection.” 21 C.F.R. §70.25.}
\footnote{138}{FDA, Color Additives and Cosmetics, supra note 135. The FDA also states that coal tar colors are “materials consisting of one or more substances that either are made from coal-tar or can be derived from intermediates of the same identity as coal-tar intermediates,” and “may also include diluents or substrata.”}
\footnote{139}{FDA, Hair Dye Products, http://www.fda.gov/Cosmetics/ProductandIngredientSafety/ProductInformation/ucm143066.htm.}
\footnote{140}{21 U.S.C. §361; FFDCA §601; Hutt, supra note 32, p. 7.}
\footnote{141}{See, e.g., The Food and Drug Administration’s Regulation of Cosmetics: Hearing Before the Subcomm. on (continued...)}
occasions, the FDA unsuccessfully has argued for the repeal of the coal tar hair dye exemption. The GAO also “recommended that FDA evaluate safety data on coal tar hair dye ingredients and require, where applicable, a cancer or other appropriate warning statement on product labels.”

FDAs have stated that “several coal-tar hair dye ingredients have been found to cause cancer in laboratory animals.” FDA unsuccessfully attempted to require the following warning on hair dyes that contained the coal tar ingredient 4-methoxy-m-phenylenediamine (4-MMPD, 2, 4-diaminoanisole): “Warning—Contains an ingredient that can penetrate your skin and has been determined to cause cancer in laboratory animals.”

Coal tar dyes are explicitly excluded from use in products intended to be dyes for eyelashes or eyebrows. To avoid an adulteration determination, coal tar hair dyes must contain the FFDCA-mandated warning statement that informs consumers of the potential risks associated with their use: “Caution – This product contains ingredients which may cause skin irritation on certain individuals and a preliminary test according to accompanying directions should first be made. This product must not be used for dyeing the eyelashes or the eyebrows; to do so may cause blindness.”

Nanomaterial Ingredients

The inclusion of nanomaterial ingredients in cosmetics has generated debate over the safety of nanomaterials and how and whether FDA should regulate such ingredients. Nanotechnology involves the application and manipulation of small matter “at the nanoscale, which is about 1 to

(...continued)


142 See, e.g., The Review of the Adequacy of Existing Laws Designed to Protect the Public from Exposure to Cancer Causing and Other Toxic Chemicals in Hair Dyes and Cosmetic Products: Hearings Before the Subcomm. on Oversight and Investigations of the House Comm. on Interstate and Foreign Commerce, 95th Cong., Serial No. 95-91 (January 23 and 26, February 2-3, 1978) at 370 (statement of Hon. Donald Kennedy, FDA Commissioner) (“But our ability to protected the public, particularly from the risk associated with long-term use of hair dyes, will continue to be severely limited until Congress repeals the exemptions for coal tar hair dye products. We have long stated that the coal tar exemptions of section 601(a) and (e) 602(e) should be repealed.”); Ahart Statement, supra note 124, at 4; Gardner Statement, supra note 129, at 6 (“The law does contain an exemption for coal tar hair dyes from the principal adulteration provisions of the act. ... We have long urged that this outmoded exemption be eliminated, and the Department will shortly submit legislation that will accomplish this purpose.”).

143 Ahart Statement, supra note 141, p. 4.

144 FDA, Hair Dye Products, supra note 139.

145 21 C.F.R. §740.18; see 47 Fed. Reg. 7829 (February 23, 1982), which stayed this regulation until further notice, effective September 18, 1980; FDA, Hair Dye Products, supra note 124.

146 21 U.S.C. §361; FFDCA §601; 21 C.F.R. §70.3(u).

147 21 U.S.C. §361(a); FFDCA §601(a). In addition to the warning label, coal tar hair dyes must have “adequate directions for preliminary patch testing” to meet the exemption from the FFDCA §601(a) adulteration provisions. 21 C.F.R. §70.3(u).
100 nanometers.\textsuperscript{148} The cosmetic industry has used nanotechnology in cosmetic products for more than two decades.\textsuperscript{149} Cosmetics are reportedly “the most prominent nanotechnology products on the U.S. market,”\textsuperscript{150} and the “global market for cosmetics using nanotechnology [was] projected to reach an estimated $155.8 million in 2010.”\textsuperscript{151} Nanomaterials are reportedly used in two main ways in cosmetic products—as UV filters and as delivery systems.\textsuperscript{152} The Project on Emerging Nanotechnologies—created in 2005 as a partnership between the Pew Charitable Trusts and the Woodrow Wilson International Center for Scholars—maintains a searchable database of consumer products, including cosmetics, that reportedly contain nanomaterials.\textsuperscript{153} Cosmetic products with nanomaterials include facial cosmetic products, from creams and moisturizers to bronzers and blushers to mascara.\textsuperscript{154}

There is debate among the scientific community as to the potential health effects of these particles. In general, the concerns about the use of nanomaterials in FDA-regulated products surround whether the small size of these particles leads to any new toxicological properties or harmful health effects, such as potentially damaging the skin or “crossing into the bloodstream, cells, and organs.”\textsuperscript{155} The unique size and chemical properties of these materials has led to concerns that they may have an increased ability to permeate the human skin and may release toxins into the bloodstream.\textsuperscript{156} Damaged skin may be “especially at risk for nanoparticle penetration.”\textsuperscript{157} Other issues may include access to the body by inhalation, ingestion, or skin penetration; the length of time that they remain in the body; the dose likely to cause harm; the effects of long-term exposure; and the impact on the environment.\textsuperscript{158} Consumer groups such as Friends of the Earth, the International Center for Technology Assessment, and Consumers Union have raised concerns about nanomaterials in cosmetic products and have petitioned FDA regarding the regulation of products containing nanomaterials.\textsuperscript{159}

\begin{itemize}
  \item \textsuperscript{149}Nanotechnology has been used in clear sunscreens and “deep-penetrating therapeutic cosmetics” since 1999 to the early 2000s. NNI, Nanotechnology Timeline, http://www.nano.gov/nanotech-101/timeline.
  \item \textsuperscript{150}Johnson, supra note 48, p. 88.
  \item \textsuperscript{154}The Project on Emerging Nanotechnologies, Health and Fitness, Cosmetics, http://www.nanotechproject.org/inventories/consumer/browse/categories/health_fitness/cosmetics/.
  \item \textsuperscript{155}Abramowitz, supra note 61, p. 203-04.
  \item \textsuperscript{157}Abramowitz, supra note 61, p. 207.
  \item \textsuperscript{158}Ibid. at 203, 207.
\end{itemize}
Nanotechnology Task Force

In 2006, then-acting FDA Commissioner Andrew von Eschenbach created an internal FDA Nanotechnology Task Force to “determin[e] regulatory approaches that encourage the continued development of innovative, safe and effective FDA-regulated products that use nanotechnology materials.”160 Neither FDA nor the task force adopted a definition of “nanotechnology.”161 The agency has stated that it “believes that the existing battery of pharmacotoxicity tests is probably adequate for most nanotechnology products that [it] will regulate.”162 In 2007, FDA declined to adopt labeling requirements for products containing nanomaterials, stating that:

Because the current science does not support a finding that classes of products with nanoscale materials necessarily present greater safety concerns than classes of products without nanoscale materials, the [FDA] does not believe there is a basis for saying that, as a general matter, a product containing nanoscale materials must be labeled as such. Therefore, [FDA] is not recommending that the agency require such labeling at this time. Instead, [FDA] recommends ... the following action: Address on a case-by-case basis whether labeling must or may contain information on the use of nanoscale materials.163

Therefore, FDA has not promulgated specific regulations requiring products that contain nanomaterials to be labeled accordingly. The Nanotechnology Task Force indicated that regulatory decisionmaking “depends in part on having staff with expertise” in the appropriate areas and recommended that FDA build in-house expertise.164 Also in 2007, the Nanotechnology Task Force recommended the agency coordinate with other federal agencies, the private sector, and other countries on research and other activities “to increase scientific understanding and facilitate assessment of data needs for regulated products” and undertake actions such as the development of guidance documents.165

Draft Guidance Regarding the Use of Nanomaterials in FDA-Regulated Products

On June 14, 2011, FDA issued draft guidance with recommendations for industry on “Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology,”

(...continued)


164 Ibid. at 14, 16.

165 Ibid. at 15-16, 30, 32.
including the implications of using nanomaterials on the regulatory status of a product or the product’s “safety, effectiveness, or public health impact.” The draft guidance is intended to assist industry and others to identify potential consideration for “regulatory status, safety, effectiveness, or public health impact” that may arise with the application of nanotechnology in all FDA-regulated products, including cosmetics. The agency states that it “does not categorically judge all products containing nanomaterials or otherwise involving the application of nanotechnology as intrinsically benign or harmful.” However, FDA also notes that “evaluations of safety, effectiveness or public health impact of such products should consider the unique properties and behaviors that nanomaterials exhibit.”

On April 25, 2012, FDA issued draft guidance on the “Safety of Nanomaterials in Cosmetic Products.” This draft guidance provides a general framework for (1) assessing the safety of cosmetic products; (2) points to consider in assessing the safety of nanomaterials in cosmetic products, including a schema for characterizing the properties of nanomaterials and considerations for toxicology testing; and (3) a summary of FDA’s recommendations. It notes that the use of nanomaterials “may alter the bioavailability of the cosmetic formulation,” and that “traditional safety tests…may not be fully applicable.” FDA concludes that the inclusion of nanomaterials in an FDA-regulated product may affect the quality, safety, effectiveness, and/or public health impact of a product, and encourages manufacturers to meet with the FDA to discuss the “test methods and data needed to substantiate the product’s safety, including short-term toxicity and long-term toxicity data as appropriate.”

Voluntary Cosmetic Registration Program

As noted above, FDA does not currently have the authority to mandate registration of cosmetic facilities, in contrast with the statutory registration requirements for establishments that produce other products regulated by the agency. However, since 1974, FDA, in cooperation with the cosmetic industry, has had a Voluntary Cosmetic Registration Program (VCRP) to facilitate registration of cosmetic establishments. GAO has noted that “[r]egistration is important

166 FDA, Draft Guidance, supra note 162, also available at http://www.gpo.gov/fdsys/pkg/FR-2011-06-14/pdf/2011-14643.pdf. The draft guidance was issued the same day as a White House memorandum to executive branch departments and agencies on policy principles regarding U.S. regulation and oversight of nanotechnology and nanomaterials. Memorandum from John P. Holdren, Director, Office of Science and Technology Policy, et al., to the Heads of Executive Departments and Agencies, Policy Principles for the U.S. Decision-Making Concerning Regulation and Oversight of Applications of Nanotechnology and Nanomaterials, June 9, 2011.

167 FDA, Draft Guidance, supra note 162.

168 Ibid.

169 Ibid.


171 Ibid.

172 Ibid.

because it serves as the basis for determining where FDA will conduct its inspections.\(^{174}\) FDA has also stated that VCRP information helps the Cosmetic Ingredient Review program (discussed previously) “in determining its priorities for ingredient safety review.”\(^{175}\)

Under VCRP, FDA encourages cosmetic establishments that manufacture or package cosmetic products to voluntarily register their facilities within 30 days of the start of their operations, regardless of whether their products enter interstate commerce.\(^{176}\) FDA regulations request that foreign cosmetic product manufacturers voluntarily register with the agency if their products are exported for sale in the United States.\(^{177}\) Cosmetic manufacturers and packagers also are encouraged to report the ingredients used in their product formulations.\(^{178}\) FDA does not assess a fee for the voluntary registration of a cosmetic product establishment.\(^{179}\)

Certain classes of establishments are exempt from FDA’s voluntary registration request “because the [FDA] Commissioner has found that such registration is not justified.”\(^{180}\) These include beauty shops; cosmetologists; retailers; pharmacies; physicians; hospitals; clinics; public health agencies; persons who compound cosmetics at a location but do not otherwise manufacture or package cosmetics from that location; and persons who manufacture, prepare, compound, or process cosmetic products for activities such as teaching or research, but not for sale.\(^{181}\)

Consumer safety organizations such as the Environmental Working Group have submitted comments to the FDA supporting the inclusion of “for professional use only” products in the voluntary registration scheme, particularly in light of issues with “Brazilian Blowout” products (see section “‘For Professional Use Only’ Labeling” and the Appendix).\(^{182}\) In its response to the comments, FDA disagreed with the inclusion of professional use products in the VCRP, as the VCRP does not apply to products not in commercial distribution.\(^{183}\)

---

\(^{174}\) GAO, Cosmetics Regulation: Information on Voluntary Actions Agreed to by FDA and the Industry, Report to the Chairman, Subcommittee on Regulation, Business Opportunities, and Energy, House Committee on Small Business, GAO/HRD-90-58, at 3 (March 1990). The GAO report also commented on a “major disagreement” between FDA and the cosmetic industry’s trade group as to the number of companies that were not registered with FDA and stated that FDA’s inability to require registration inhibited the agency’s ability to “accurately assess how many companies may be avoiding registration.” Ibid. pp. 3-4.

\(^{175}\) FDA, Voluntary Cosmetic Registration Program (VCRP), http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/VoluntaryCosmeticsRegistrationProgramVCRP/default.htm.

\(^{176}\) 21 C.F.R. §§710.1, 710.2.

\(^{177}\) 21 C.F.R. §710.1.

\(^{178}\) 21 C.F.R. §720.4.

\(^{179}\) 21 C.F.R. §710.9.

\(^{180}\) 21 C.F.R. §710.9.

\(^{181}\) “FDA disagrees with the suggested change to its registration program. Cosmetic products marketed in the United States are regulated by FDA in accordance with the requirements of the [FFDCA] and, if offered for sale as consumer commodities, the [FPLA]. The FPLA defines a consumer commodity as a product distributed through retail sales for consumption by individuals. Professional products used in salons, and free samples are not available through retail sale to consumers, so they are not considered to be in ‘commercial distribution.’ Because the VCRP program only applies to cosmetic products in commercial distribution as defined in the FPLA, FDA is unable to file professional cosmetic products.” Letter from Thomas Cluderay, Staff Attorney and Stabile Fellow, Environmental Working Group, EWG Comments on FDA’s Voluntary Cosmetic Registration Program, Docket No. FDA-2010-N-0623 (February 11, 2011); see also Alaina Busch, Mandatory Cosmetics Adverse Events Reporting Urged, FDA Week, April 15, 2011.

\(^{182}\) FDA, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Cosmetic Registration Program, 76 Fed. Reg. 10607, 10608 (February 25, 2011).
FDA also disagreed with the suggested audit of the cosmetics industry, which the consumer group proposed in order “to determine the current participation rate” in the VCRP and “to estimate how many ingredients and products FDA receives into the database compared to the total produced.” The agency focused on its lack of “statutory authority to make registration in the VCRP mandatory,” as well as “the cost of completing such a project,” calling the audit “not a wise use of Agency funds in the current economic environment.” Finally, FDA disagreed “at this time” with the Environmental Working Group’s suggestion to create a certification program so that cosmetic companies could “indicate to consumers that they have participated in the VCRP,” stating that the agency would need to research “how consumers would interpret such a certification claim,” as well as how to enforce registration claims.

Report of Adverse Reactions to Cosmetics

FDA lacks the statutory authority to require cosmetic manufacturers to notify FDA of adverse events associated with their products and to require cosmetic companies to report information they receive from consumers and others regarding adverse events. Currently, the agency advises consumers to self-report “negative reaction[s] to a beauty, personal hygiene, [and] makeup products” to the FDA via the agency’s safety information and adverse event reporting program—MedWatch—or the consumer’s local FDA complaint coordinator. The agency is interested in hearing from consumers who “experience a rash, hair loss, infection, or other problem—even if they didn’t follow product directions,” as well as when products have bad smells or unusual colors and may be contaminated. The agency may use adverse event reports by consumers to detect repeated problems with a product and potentially to take enforcement or other legal action.

For example, adverse events that have been reported to FDA include reactions to henna/mehndi, certain shades of ink used for tattoos and permanent makeup, and keratin hair treatment products. Temporary tattoos have been associated with reports of allergic reactions. These products also have been subject to an import alert due to the lack of a required ingredient declaration on the label or the presence of colors not approved for use in cosmetics for the skin.

---

184 Ibid.; see also Alaina Busch, FDA Rejects Cosmetics Certification Program Recommendation, FDA Week, March 3, 2011.
186 Ibid.
189 Ibid. Data to be reported to the FDA include “the name and contact information for the person who had the reaction; the age, gender, and ethnicity of the product’s user; the name of the product and manufacturer; a description of the reaction—and treatment, if any; the healthcare provider’s name and contact information, if medical attention was provided; and when and where the product was purchased.”
190 Ibid.
193 Ibid.
Certain ink shades used for permanent makeup resulted in “more than 150 reports of adverse reactions in consumers.”

FDA has also received at least 33 adverse event reports, an additional seven reports of hair loss, and a number of inquiries concerning the safety of “Brazilian Blowouts” and similar “For Professional Use Only” hair treatment products, which may contain or release formaldehyde in the air when used by hairdressers to smooth hair, despite being labeled as “formaldehyde-free.” The Occupational Safety and Health Administration (OSHA), which regulates workers’ exposure to formaldehyde and workplace safety, and state agencies that regulate hair salons have issued hazard alerts about these products. This issue is discussed further in the Appendix.

In the absence of FDA requirements regarding adverse event reporting, the cosmetic industry has made efforts to self-regulate. In 2007, the industry trade association, the Personal Care Products Council (PCPC), created a Consumer Commitment Code that cosmetic product and ingredient manufacturers and marketers were “encouraged to acknowledge their support of” in writing. One of the Code’s principles is that “a company should notify the FDA of any known serious and unexpected adverse event as a result of the use of any of its cosmetic products marketed and used in the United States,” where the terms “serious” and “unexpected” mean the same as FDA regulations defining serious and unexpected adverse events for drugs. This Code is not a binding legal standard and cannot be enforced by FDA. The PCPC has stated that it “will not terminate the Council’s membership for noncompliance,” but would instead encourage compliance with the Code.

Other Concerns with Labeling

Consumers may seek out particular cosmetics based on their labeling, such as cosmetics made with organic ingredients or without being tested on animals. However, FDA does not define certain terms used by manufacturers on their cosmetic products. Sections below on “organic” and “not tested on animals” claims address slight differences in how cosmetic products are marketed.
using certain claims and what consumers may believe such claims to mean. Additionally, not all cosmetic products are required to be labeled in the same manner, as the section below on products used by professionals discusses.

“Organic” Labeling Claims on Cosmetic Products

As with many statements made on cosmetic products, the terms “natural” and “organic” have no specific definition in the FFDCA, which may lead to consumer confusion. While FDA has authority for labeling of cosmetics, the agency does not regulate the use of the term “organic”—rather, USDA regulates “organic” claims on cosmetic products. Generally speaking, some cosmetics may be labeled as “natural” and “market[ed] ... as containing plant or mineral ingredients,” while other cosmetic labels may include the claims that they are “organic” or made from “agricultural ingredients grown without pesticides.” Consumers seeking “natural” or “organic” cosmetics may have different expectations about the materials in a product marketed as natural or organic.

Consumers may perceive that products that are labeled as “natural” or “organic” have a health benefit. However, FDA has noted that “many plants, regardless of whether they are organically grown, contain substances that may be toxic or allergenic.” Additionally, FDA has stated that “[c]onsumers should not necessarily assume that an ‘organic’ or ‘natural’ ingredient or product would possess greater inherent safety than another chemically identical version of the same ingredient.” Some natural ingredients may cause consumers to have adverse reactions, and FDA has stated that “[i]n fact, ‘natural’ ingredients may be harder to preserve against microbial contamination and growth than synthetic raw materials.”

In 2005, the USDA’s National Organic Program (NOP), which oversees voluntary organic labeling of certified foods, determined that cosmetic products that meet the requirements established under the NOP regulations are eligible for certification as “organic.” A cosmetic product “may be eligible to be certified under the NOP regulations” if the product “contains or is

202 Natasha Singer, Natural, Organic Beauty, N.Y. Times, p. G1, November 1, 2007. The lack of an FDA definition for these and similar terms may allow a cosmetic manufacturer to make such claims on “a synthetic-based shampoo with one plant derivative” as well as “a synthetic-free face powder formulated with only minerals.”
203 FDA, Center for Food Safety and Applied Nutrition, Office of Cosmetics and Colors, How Smart Are You About Cosmetics? Question 6a, http://www.accessdata.fda.gov/videos/CFSAN/costf/costf-6.html; Singer, supra note 207 (noting that “representatives for the government and the beauty industry, as well as some environmental activists, acknowledge that there is no published scientific proof to support the notion that plant-based cosmetics are safer, healthier or more effective for people”).
205 Singer, supra note 202 (quoting Dr. Linda M. Katz, Director of the FDA’s Office of Cosmetics and Colors).
206 Ibid. (quoting Dr. Linda M. Katz, Director of the FDA’s Office of Cosmetics and Colors).
207 7 C.F.R. Part 205.
208 7 C.F.R. §205.2; USDA, supra note 201.
The NOP regulations provide four organic labeling categories: (1) 100% Organic—including water and salt, the product must be made of only organically produced ingredients and may use the USDA organic seal; (2) Organic—including water and salt, the product must be comprised of at least 95% organically produced ingredients and may use the USDA organic seal; (3) Made with Organic Ingredients—including water and salt, the product must contain at least 70% organic ingredients and the label may list three of the organic ingredients or food groups, such as herbs, but the product may not use the USDA organic seal; and (4) specific ingredients may be identified as organic if they are USDA-certified organic, but these products may not use the USDA organic seal or the term “organic.”

In 2009, the Certification, Accreditation, and Compliance Committee of the USDA’s 15-member National Organics Standards Board made recommendations regarding “the problem of mislabeled organic personal care products.” The committee stated that the “USDA is responsible for product organic claims but is not currently enforcing this in the area of personal care products.” For example, some shampoos and conditioners state that they “use ingredients that are 100% Organic or are directly traceable to a natural source,” but do not indicate who performs the organic certification or display the USDA Organic Seal. As a result, the committee noted that “[c]onsumers are not assured that organic claims are consistently reviewed and applied” to personal care products. The committee recommended amending the NOP regulations to include a definition of “personal care products” that is based on the definition of a “cosmetic” under the FFDCA, to clarify the use of the term “organic” in its application to personal care products, and to restrict the use of the USDA Organic Seal. However, the recommendations of the committee have not yet been adopted by the National Organic Standards Board and “are not official USDA policy” at this time.

In addition to the USDA’s NOP, other entities have created their own standards programs for what constitutes “organic” in personal care products. For example, with input from industry stakeholders, the National Sanitation Foundation (NSF) International and the American...
National Standards Institute (ANSI)\(^{219}\) established a new nonfederal, voluntary standard, NSF/ANSI 305-2009e, for personal care products containing organic ingredients.\(^{220}\) The standard allows a labeling claim of “contains organic ingredients” to be made for products with 70% or higher organic content, if the products comply with the standard’s requirements, which include certification based on steps such as an application, on-site inspection, and technical review.\(^{221}\) The standard requires manufacturers to list the exact percent of organic content.\(^{222}\) The standard can be used for “rinse-off and leave-on personal care and cosmetic products, as well as oral care and personal hygiene products” if such products comply with “materials, processes, production criteria, and conditions” specified in the standard.\(^{223}\) The major difference between the USDA NOP regulations and the NSF/ANSI standard is that the standard “allows for limited chemical processes that are typical for personal care products,” which are “methods considered synthetic under the NOP.”\(^{224}\) According to NSF International, compliance with this standard may “provide a competitive advantage to those certified products” that contain organic ingredients.\(^{225}\)

“Not Tested on Animals” Labeling

Many cosmetic products may contain ingredients or raw materials that have been tested on animals in the past, though no animal testing of the ingredients or product currently may be occurring.\(^{226}\) While manufacturers may use “no animal testing” claims for their products, they still “may rely on raw material suppliers or contract laboratories to perform any animal testing necessary to substantiate product or ingredient safety.”\(^{227}\) It may be confusing for consumers attempting to distinguish cosmetic products with ingredients that have never been tested on animals from cosmetic products that may use or contract for the use of animal testing at some point in the product’s path to commerce.\(^{228}\)

(...continued)


\(^{221}\) NSF, Q&A, supra note 218.

\(^{222}\) NSF, Q&A, supra note 218.


\(^{224}\) NSF, Q&A, supra note 218.

\(^{225}\) Ibid.


\(^{227}\) Ibid.

Some companies promote their products as not having been tested on animals, either because they contain all-natural ingredients or by labeling with such terms as “finished product not tested on animals,” “no animal ingredients,” or “cruelty free.” FDA does not define or prescribe the use of these terms. In the absence of federal regulation on the use of such terms, animal rights groups have created programs where companies that self-certify that they are “cruelty free” may license the organization’s logo for use on their products.229

“For Professional Use Only” Labeling

Certain information that is not required to appear in cosmetic product labeling may nonetheless be of interest to consumers and professionals who use and apply “for professional use only” cosmetic products. (The Appendix discusses the hazards potentially associated with one type of “for professional use only” product applied in keratin hair treatments, which are also known as Brazilian Blowouts.) This section provides general background on “for professional use only” cosmetic products.

Cosmetics that are “consumer commodities” are required to list their ingredients, according to FDA regulations implementing the FPLA.230 The ingredient listing requirement applies to products produced or distributed for retail sale and does not apply to “for professional use only” products used only by salons, if the salon does not also offer the product for purchase by its customers.231 As a result, “cosmetologists and other professionals, as well as their clients, may not know what chemicals are in the cosmetics used in nonretail businesses, such as beauty salons.”232 However, if a cosmetic product were labeled “for professional use only” but sold at retail, the ingredients must be listed, or the cosmetic product will be considered to be misbranded.233 Ingredients used in “for professional use only” cosmetic products are not included in the VCRP.234

FDA does not define which cosmetic products are “For Professional Use Only.” Cosmetic manufacturers and beauty supply companies that produce these products may limit distribution of such products to salons and salon professionals.235 Despite manufacturer sale restrictions, some distributors have sold “for professional use only” products to retail stores, potentially in contravention of contracts or agreements between distributors and manufacturers regarding the

---

229 PETA, PETA’s Caring Consumer Program, http://www.peta.org/about/learn-about-peta/caring-consumer-program.aspx. As another example, the Coalition for Consumer Information on Cosmetics’ (CCIC) Leaping Bunny Program allows cosmetics products that meet certain criteria for non-animal tested cosmetic products to bear a “leaping bunny” logo. For this program, the company makes voluntary guarantees regarding the company’s and supplier’s commitment not to test on animals, and the CCIC may require an independent audit. Coalition for Consumer Information on Cosmetics, The Corporate Standard of Compassion for Animals (“the Standard”), http://www.leapingbunny.org/pdf/Corporate_Standard_of_Compassion_for_Animals.pdf. The independent audit is commissioned either by the company or the CCIC, depending on the company’s gross annual sales, and is performed by an accredited auditing firm. Ibid. at 2.

230 21 C.F.R. §701.3.


232 GAO report, supra note 175, at 13.


234 CIR, Final Amended Report, supra note 196, at 6.

sale of such products, as well as the misbranding prohibition of the FFDCA and related provisions in the FPLA. 236

Conclusion

Although FDA’s authorities over cosmetic products include some of those applicable to other FDA-regulated products, they are generally less comprehensive and exclude certain requirements imposed on other FDA-regulated products. The manner in which a cosmetic product could or should be regulated, however, is not always clear. FDA has issued regulations and procedures for cosmetics with which manufacturers voluntarily may choose to comply. Additionally, the cosmetic industry’s trade association has established a cosmetic ingredient review program for cosmetic manufacturers with the purpose of determining which cosmetic ingredients are safe under certain conditions of use. Nevertheless, some questions remain as to whether the FDA’s current oversight of cosmetic products and their ingredients is appropriate.

Appendix. Keratin Hair Treatments, Also Known as “Brazilian Blowouts”

Background

Keratin hair treatment products reportedly smooth frizzy hair, straighten curly hair, and reduce blow drying and straightening times. Such treatments may also be known as “Brazilian Blowouts” after the name of one company’s products commonly used for such treatments. The treatments typically cost several hundred dollars, depending on the length and texture of one’s hair, and may last from six weeks to several months, depending on the type of treatment. Many brands of keratin hair treatment products have been found to contain free formaldehyde in solution (which tends to combine with water, forming methylene glycol), or other chemicals that convert into formaldehyde gas, whether or not they are labeled as “formaldehyde-free.”

Formaldehyde and a related chemical, methylene glycol, are “known to induce a fixative action on proteins (e.g., keratin),” and therefore hair straightening solutions reportedly “maintain straightened hair by altering protein structures via amino acid crosslinking reactions, which form crosslinks between hair keratins and with added keratin from the formulation” of the hair product.

Questions have been raised about the accuracy of ingredient statements and the adequacy of safety warnings on product labels for keratin hair treatment products containing formaldehyde. Formaldehyde is a respiratory irritant and a known human carcinogen. The concern is that stylists who use such products, and consumers who are treated with them, may be exposed to harmful levels of formaldehyde without their informed consent, because many products are labeled “formaldehyde-free.” As discussed below, investigations by the National Institute for Occupational Safety and Health (NIOSH), the Occupational Safety and Health Administration (OSHA), and Health Canada have indicated that even products labeled “formaldehyde-free” may contain levels of the chemical considered potentially unsafe. While OSHA regulates workers’ exposure to formaldehyde and worker and workplace safety, as discussed below, FDA regulates cosmetic products containing formaldehyde.

Members of Congress have requested that FDA take enforcement actions against such keratin hair treatment products, and FDA has issued a warning letter indicating certain Brazilian Blowout

238 CIR, Final Amended Report, supra note 196, p. 7.
239 Keratins are hair proteins. California Department of Public Health, Occupational Health Branch, California Safe Cosmetics Program, Q&A: Brazilian Blowout & Other Hair Smoothing Salon Treatments, http://www.cdph.ca.gov/programs/cosmetics/Documents/BrazilianBlowoutQA.pdf
241 Hair salons and stylists are regulated at the state level. States may require salons and barber shops to register with the state and stylists to apply for and possess a license.
FDA Regulation of Cosmetics and Personal Care Products

products are in violation of the FFDCA. FDA is evaluating hair straightening and hair smoothing products for safety on an individual basis. The manufacturer of Brazilian Blowout products has argued that testing by OSHA and “alternate reputable institutions” indicated that its products fall below OSHA safety standards. OSHA has responded by asking the CEO of Brazilian Blowout to issue corrective statements to salon owners that “clearly stat[e] that OSHA air quality tests conducted … have yielded results above acceptable OSHA limits.”

Formaldehyde

The Environmental Protection Agency (EPA) attempts to quantify the risk that an individual will suffer adverse health effects due to particular levels of exposure to a chemical. According to EPA, formaldehyde:

- can cause watery eyes, burning sensations in the eyes and throat, nausea, and difficulty in breathing in some humans exposed at elevated levels (above 0.1 parts per million). High concentrations may trigger attacks in people with asthma. There is evidence that some people can develop a sensitivity to formaldehyde. It has also been shown to cause cancer in animals and may cause cancer in humans. Health effects include eye, nose, and throat irritation; wheezing and coughing; fatigue; skin rash; severe allergic reactions. May cause cancer.

The federal Agency for Toxic Substances and Disease Registry (ATSDR) concurs and adds that exposure may lead to:

- neurological effects, and increased risk of asthma and/or allergy … in humans breathing 0.1 to 0.5 [parts formaldehyde per million parts of air (ppm)]. Eczema and changes in lung function have been observed at 0.6 to 1.9 ppm. Decreased body weight, gastrointestinal ulcers, and liver and kidney damage were observed in animals orally exposed to 50–100 mg/kg/day formaldehyde.

(...continued)

regulated at the state level. States may require salons and barber shops to register with the state and stylists to apply for and possess a license.


247 EPA, An Introduction to Indoor Air Quality (IAQ), Formaldehyde, http://www.epa.gov/iaq/formaldehyde.html#HealthEffects. EPA is conducting a risk assessment for formaldehyde in order to update information in its Integrated Risk Information System (IRIS), a database of chemical toxicity information. A 1991 IRIS assessment classified formaldehyde as a probable human carcinogen. EPA currently is revising a draft updated risk assessment based on comments from reviewers at the National Academy of Sciences.

The 12th Report on Carcinogens (ROC), issued by the U.S. Department of Health and Human Services’ (HHS) National Toxicology Program (NTP) in June 2011 changed the classification of formaldehyde from “reasonably anticipated to be a human carcinogen” to “known to be a human carcinogen,” based on its criterion that there is “sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance, or mixture, and human cancer.” This ROC listing does not necessarily mean that formaldehyde will cause an exposed individual to develop cancer; rather, it means that at some sufficient level of exposure to formaldehyde some humans will develop cancer.

The World Health Organization’s International Agency for Research on Cancer (IARC) listed formaldehyde as a carcinogen in 2006. OSHA recognizes the IARC list of carcinogens as well as the NTP ROC list for the purposes of its hazard communication standard, discussed below.

**OSHA Formaldehyde Standards**

Workers’ exposure to formaldehyde in general industries as well as shipyard employment and construction is regulated at the federal level and is addressed in OSHA standards or equivalent regulations in OSHA-approved state plans. OSHA has issued rules on formaldehyde exposure limits, protective equipment, and cancer warning labels for products that contain formaldehyde. The agency also notes that “[s]hort-term exposure to formaldehyde can be fatal,” and that “[l]ong-term exposure to low levels of formaldehyde may cause respiratory difficulty, eczema, and sensitization.”

OSHA’s formaldehyde standard “applies to all occupational exposures to formaldehyde, i.e. from formaldehyde gas, its solutions, and materials that release formaldehyde.” OSHA’s formaldehyde standard states that “[t]he permissible exposure limit (PEL) for formaldehyde in the workplace is 0.75 parts formaldehyde per million parts of air (0.75 ppm) measured as an 8-hour time-weighted average.” The standard also has short-term exposure limits of 2 ppm per 15-minute time period and sets a level at which “increased industrial hygiene monitoring and initiation of worker medical surveillance” is triggered. OSHA notes that an “airborne concentration of formaldehyde above 0.1 ppm can cause irritation of the respiratory tract.”

Employers who have workplaces covered by the OSHA standard are required to monitor their employees’ exposure to formaldehyde. OSHA requires communication of formaldehyde’s potential health hazards for “[f]ormaldehyde gas, all mixtures or solutions composed of greater

---

252 Ibid.
253 Ibid.
254 29 C.F.R. §1910.1048(a).
255 29 C.F.R. §1910.1048(c).
256 Ibid.
257 Ibid.
258 29 C.F.R. §1910.1048(d).
than 0.1 percent formaldehyde, and materials capable of releasing formaldehyde into the air, under reasonably foreseeable conditions of use, at concentrations reaching or exceeding 0.1 ppm.\textsuperscript{259} Employers are required to ensure that such products have hazard warning labels if they are “capable of releasing formaldehyde at levels of 0.1 ppm to 0.5 ppm,” and if the products are “capable of releasing formaldehyde at levels above 0.5 ppm,” the labels must contain additional information and the words “Potential Cancer Hazard.”\textsuperscript{260} Additionally, manufacturers and distributors of formaldehyde-containing products that meet the 0.1 percent level must “assure that material safety data sheets and updated information are provided to all employers purchasing such materials.”\textsuperscript{261} Based on a settlement with the California Attorney General, the website for the Brazilian Blowout products now contains a Material Safety Data Sheet for Brazilian Blowout Acai Professional Smoothing Solution, which indicates that the product is classified as a hazardous substance and warns about using proper ventilation.\textsuperscript{262}

### Adverse Event Reports

Hair salon stylists in Oregon first raised concerns about a hair smoothing product labeled “formaldehyde-free” when they began experiencing nosebleeds within a month of using the product and reportedly later developed chest pain and sore throats.\textsuperscript{263} One stylist contacted the Oregon Health and Science University’s Center for Research on Occupational and Environmental Toxicology, which conducted an investigation in 2010 with the Oregon Occupational Safety and Health Division.\textsuperscript{264} Researchers found significant formaldehyde levels in 105 samples of hair smoothing treatments from 54 different salons.\textsuperscript{265} Oregon’s Occupational Safety and Health Division then issued alerts about the formaldehyde levels to over 21,000 state-licensed hair stylists.\textsuperscript{266} Although products such as the Brazilian Blowout Acai Professional Smoothing Solution were labeled “formaldehyde-free,” the tests found that the products had an average formaldehyde content of more than 8%.\textsuperscript{267} Some products contained amounts of formaldehyde “well above what could legally be labeled as ‘formaldehyde-free.’”\textsuperscript{268}

Oregon’s Occupational Safety and Health Division received reports of adverse events from stylists across the United States after its alert, which included “burning of eyes and throat, watering of eyes, dry mouth, loss of smell, headache and a feeling of ‘grogginess,’ malaise, shortness of breath and breathing problems, a diagnosis of epiglottitis attributed by the stylist to

\textsuperscript{259} 29 C.F.R. §1910.1048(m).
\textsuperscript{260} 29 C.F.R. §1910.1048(m)(3).
\textsuperscript{261} 29 C.F.R. §1910.1048(m)(4).
\textsuperscript{264} Oregon OSHA, supra note 264, at 1.
\textsuperscript{265} Ibid. at 2.
\textsuperscript{266} Muldoon, supra note 264.
\textsuperscript{267} Oregon OSHA, supra note 264, p. 2.
their use of the product, fingertip numbness, and dermatitis,” as well as reports of hair loss.\footnote{269} FDA has received reports from state and local groups of “eye irritation, breathing problems, and headaches,” as well as adverse event reports from “hair stylists, their customers, and individual users” of similar symptoms, plus fainting, bronchitis, inhalation pneumonitis, and vomiting.\footnote{270} Similarly, Health Canada reportedly received adverse reaction reports for hair products with formaldehyde from 50-60 individuals, which included “burning eyes, nose, throat and breathing difficulties, with one report of hair loss,” as well as reports of “headache, arthritis, dizziness, epistaxis [nosebleeds], swollen glands, and numb tongue.”\footnote{271}

**NIOSH and OSHA Investigations**

In December 2010, NIOSH conducted a health hazard evaluation of the Brazilian Blowout Acai Professional Smoothing Solution, as used by one hair stylist employee on another hair stylist in a salon.\footnote{272} The evaluation indicated that the solution’s concentration of formaldehyde (greater than 0.1%) was enough to merit the “hazard communication requirements of the OSHA formaldehyde standard.”\footnote{273} OSHA has conducted its own investigations of keratin treatment products.\footnote{274} OSHA’s investigations “found formaldehyde in the air when stylists used hair smoothing products,” even though not all of the products had “formaldehyde listed on their labels or in material safety data sheets as required by law.”\footnote{275} OSHA air tests of one product labeled as “formaldehyde-free” exceeded OSHA’s limits on formaldehyde.\footnote{276} OSHA has issued at least one citation to an employer after air sampling found that salon workers “were exposed to formaldehyde levels that exceeded OSHA’s 15-minute short term exposure limit.”\footnote{277}

OSHA issued a Hazard Alert to hair salons indicating the hazards associated with the use of hair smoothing treatment products and the responsibilities of salons that use these products under the federal Occupational Safety and Health Act.\footnote{278} California and several other states have issued similar notices.\footnote{279} In August 2011, the CEO of Brazilian Blowout sent a letter to salon owners indicating that “all OSHA and independent air-quality tests conducted on the Brazilian Blowout Professional Smoothing Solution … have yielded results well-below even the most stringent of

\footnotesize{269} CIR, Final Amended Report, supra note 196, p. 11. Epiglottitis is inflammation of tissues in the back of the throat.
\footnotesize{270} Ibid. Pneumonitis is inflammation of the lungs.
\footnotesize{271} CIR, Final Amended Report, supra note 196, at 11.
\footnotesize{273} Ibid. at 6.
\footnotesize{274} OSHA, Hazard Alert, supra note 269.
\footnotesize{275} FDA, FDA Receives Complaints Associated With the Use of Brazilian Blowout, (May 24, 2010), http://www.fda.gov/Cosmetics/ProductandIngredientSafety/ProductInformation/ucm228898.htm.
\footnotesize{276} Ibid.
OSHA standards.\(^{280}\) In September 2011, OSHA issued a letter to the Brazilian Blowout CEO informing him that OSHA disagreed with his remarks and requesting that he immediately take corrective actions such as sending a correction or retraction to his letter to salon owners, “clearly stating that OSHA air quality tests conducted … have yielded results above acceptable OSHA limits.”\(^{281}\)

**Actions by Other Countries**

In 2011, Health Canada issued an advisory naming eleven keratin or similar smoothing hair treatment products with levels of formaldehyde ranging from 0.35% to 8.4%, which exceed the level of 0.2% at which it is “permitted as a preservative” in Canada.\(^{282}\) Therefore, “hair smoothing products with formaldehyde levels” above 0.2% are banned from being sold in Canada.\(^{283}\) This 0.2% level for formaldehyde and its equivalents is also the upper limit recommended by the Cosmetic Ingredient Review panel.\(^{284}\) Authorities in France and Germany have warned against the use of hair smoothing products with high concentrations of formaldehyde, and both France and Ireland took steps to remove products from the market.\(^{285}\)

**Cosmetic Ingredient Review Analysis**

The Cosmetic Ingredient Review (CIR) recently re-evaluated the safety of formaldehyde and addressed the safety of methylene glycol, a compound formed when formaldehyde is combined with water, in cosmetic products.\(^{286}\) As mentioned in the body of this report, under the CIR program, expert panels analyze information on the safety of ingredients used in cosmetic products. In October 2011, CIR issued a final amended report on formaldehyde and methylene glycol that stated that “[n]ot surprisingly, formaldehyde is an irritant at low concentration, especially to the eyes and the respiratory tract. Formaldehyde exposure can result in a sensitization reaction.”\(^{287}\) CIR stated that its panel “continues to believe that formaldehyde gas can produce [nasopharyngeal] cancers at high doses.”\(^{288}\)

CIR’s expert panel “was concerned” with adverse event reports, which it noted were “consistent with measured air levels of formaldehyde in salons” using hair straightening products and indicated that not all ventilation controls were effective in allowing for safe use.\(^{289}\) CIR cited the


\(^{281}\) Ibid.


\(^{283}\) CIR, Final Amended Report, supra note 196, p. 7.

\(^{284}\) Ibid. p. 17. “[I]n no case should the formalin concentration exceed 0.2% (w/w), which would be 0.074% (w/w) calculated as formaldehyde or 0.118% (w/w) calculated as methylene glycol.”

\(^{285}\) CIR, Final Amended Report, supra note 196, p. 7.

\(^{286}\) Ibid. p. 8.

\(^{287}\) Ibid. p. 17.

\(^{288}\) Ibid. pp. 17-18.
Oregon Occupational Safety and Health Division’s workplace survey of ventilation efforts that ranged from “a building HVAC system, propping the business’s doors open, or operating ceiling fans.”

The CIR panel concluded that “[i]n the present practices of use and concentration (on the order of 10% formaldehyde/methylene glycol, blow drying and heating up to 450°F with a flat iron, inadequate ventilation, resulting in many reports of adverse effects), hair smoothing products containing formaldehyde and methylene glycol are unsafe.” However, CIR found that formaldehyde and methylene glycol “are safe for use in cosmetics when formulated to ensure use at the minimal effective concentration, but in no case should the formalin [formaldehyde and water solution] concentration exceed 0.2%.” As an example, the panel discussed the use and concentration of formaldehyde and methylene glycol in nail hardening products.

An Assessment of FDA’s Authorities

Some Members of Congress and the chief scientist of an industry trade association have asked FDA to take action on keratin hair treatment products. This section discusses FDA’s existing authorities and potential actions that the agency could take with regard to such cosmetic products, as well as the warning letter that FDA has issued to the CEO of Brazilian Blowout and actions by the California Attorney General. FDA does not have authority to regulate “the operation of salons or the practice of cosmetology.”

FDA does not ban formaldehyde or methylene glycol in cosmetic products. According to the CIR, FDA’s voluntary cosmetic registration program contained 77 uses of formaldehyde and formaldehyde solution (formalin). FDA has stated that the safety of formaldehyde “as a cosmetic ingredient depends on a variety of factors, such as its concentration in the final product and how the final product is used.” FDA could issue a rule prohibiting or restricting the use of formaldehyde and formaldehyde solutions in cosmetic products if the agency concluded that such substances were poisonous or deleterious. If such ingredients were deemed deleterious, their

---

290 Ibid. p. 7.
291 Ibid. p. 3, 18.
292 CIR, Final Amended Report, supra note 196, pp. 19, 22. This amount “would be 0.074%(w/w) calculated as formaldehyde or 0.118%(w/w) calculated as methylene glycol.”
293 Ibid. at 22.
294 The Chief Scientist of the Personal Care Products Council has issued a statement recommending that FDA “take prompt and appropriate action to make sure these products have been fully tested and substantiated for safety under their conditions of use.” Additionally, the PCPC “strongly advise[d] consumers and beauticians not to use professional hair straightening products in the home,” and to ensure that salons that offer such treatments have proper ventilation. Press Release, Statement by John Bailey, Chief Scientist, Personal Care Products Council, on Cosmetic Ingredient Review (CIR) Expert Panel Preliminary Findings on Safety of Two Ingredients Used in Professional Hair Smoothing Products (March 9, 2011), http://www.personalcarecouncil.org/newsroom/20110309.
297 CIR, Final Amended Report, supra note 196, p. 6.
298 Letter from Phil Broadbent, supra note 296 (citing FDA, Nail Care Products, http://www.fda.gov/Cosmetics/ProductandIngredientSafety/ProductInformation/ucm127068.htm#forma).
299 21 C.F.R. §700.11-700.27.
Inclusion in a cosmetic product would render the product adulterated under the FFDCA. FDA does not require a warning label on cosmetic products containing formaldehyde, formalin, methylene glycol, or related chemicals. However, FDA is authorized to conduct rulemaking to require a warning statement on cosmetic products with such ingredients. FDA regulations provide that “[t]he label of a cosmetic product shall bear a warning statement whenever necessary or appropriate to prevent a health hazard that may be associated with the product.”

FDA may take enforcement actions against adulterated or misbranded cosmetic products, such as cosmetic products with misleading labels. Labeling must be deemed to be misleading if it does not reveal material facts “in light of other representations made or suggested by statement, [or] word.” FDA has indicated that the omission of material facts on the labeling of keratin hair treatment products—i.e. labeling these products “formaldehyde-free” when they in fact contain formaldehyde—could make such products misbranded under the FFDCA.

In August 2011, FDA issued a warning letter to the CEO of Brazilian Blowout, noting that the product was both adulterated and misbranded under the FFDCA. FDA asserted that the product was adulterated because the cosmetic “bears or contains a deleterious substance [methylene glycol] that may render it injurious to users under the conditions of use prescribed in your labeling.” Additionally, FDA stated that the product was misbranded because “its label and labeling (including instructions for use) makes misleading statements regarding the product’s ingredients and fails to reveal material facts with respect to consequences that may result from the use of the product.” FDA advised the CEO to take corrective actions or face potential enforcement actions, including seizures and injunctions, and emphasized that manufacturers have a duty to ensure the products they market are safe and in compliance with FDA requirements.

Depending on how “formaldehyde free” hair keratin products have been advertised, the Federal Trade Commission also may be authorized to initiate an action for deceptive advertising. Action by state attorneys general may also be possible. The California Attorney General’s office filed a lawsuit against one company for labeling violations, deceptive advertising, and violations of state cosmetics and toxics acts. The lawsuit resulted in a settlement with the manufacturer.

300 21 U.S.C. §361(a); FFDCA §601(a).
301 FFDCA §§301, 303.
302 21 C.F.R. §740.1(a).
303 21 C.F.R. §1.21(a)(1).
304 Letter from Phil Broadbent, supra note 296.
306 Ibid. (referencing 21 U.S.C. §361(a)).
307 Ibid. (referencing 21 U.S.C. §321(n)).
308 Ibid.
310 California’s Department of Public Health released a question and answer document in response to inquiries from hair stylists and customers that indicated that employers were required by California’s OSHA standards “to protect their employees from exposure to hazardous airborne chemicals in California workplaces.” California Department of Public Health, Occupational Health Branch, California Safe Cosmetics Program, Q&A: Brazilian Blowout & Other Hair (continued...)
requiring a “CAUTION” warning on two of its products (including a California Proposition 65 cancer warning); the production of a Material Safety Data Sheet and its posting on the company’s website; the end of deceptive advertising, including modifications to the company’s website; retesting of products at approved laboratories; reporting to the California Department of Public Health Safe Cosmetics Program; the disclosure of refund policies; proof of professional licensing before sale of professional use only products; civil penalties; and attorneys fees.\textsuperscript{311}

As discussed earlier in this report, FDA does not have the authority to require premarket approval or premarket review of cosmetic ingredients or cosmetic products, except for color additives.\textsuperscript{312} Additionally, FDA cannot mandate that a company recall a product that may violate the FFDCA or FPLA, but the agency can request that a manufacturer voluntarily recall a cosmetic product.\textsuperscript{313} Nor does the agency have the authority to mandate adverse event reports for interactions that consumers experience from the use of a company’s products. However, as indicated earlier, FDA has encouraged consumer reporting of adverse events associated with cosmetics. The agency’s website discusses complaints regarding the use of Brazilian Blowout and other hair smoothing products and urges consumers and salon professionals to report adverse events to FDA.\textsuperscript{314}

Finally, FDA cannot require professional use cosmetic products, such as Brazilian Blowout, to list their ingredients if they are not “consumer commodities”—products produced or distributed for retail sale—under the FPLA.\textsuperscript{315} However, if a cosmetic product was labeled “for professional use only” but sold at retail, the ingredients must be listed, or the cosmetic will be considered to be misbranded.\textsuperscript{316} FDA stated in November 2010 that it was “investigating whether or not Brazilian Blowout is marketed directly to consumers. If so, failure to comply with the ingredient declaration requirement would constitute misbranding.”\textsuperscript{317}

\section*{Author Contact Information}

(name redacted)
Analyst in Public Health and Epidemiology
[redacted]@crs.loc.gov, 7-....

(......continued)
\textsuperscript{312} 21 C.F.R. §721.
\textsuperscript{313} Letter from Phil Broadbent, supra note 296.
\textsuperscript{315} 21 C.F.R. §701.3.
\textsuperscript{317} Letter from Phil Broadbent, supra note 296.
Acknowledgments

Carrie Newton Lyons, Section Research Manager/Legislative Attorney; Irma E. Arispe, Section Research Manager; (name redacted), former Legislative Attorney; (name redacted), Specialist in Public Health and Epidemiology; (name redacted), former Specialist in Nutrition and Food Safety; (name redacted), Specialist in Environmental Policy; and Scott Szymendera, Analyst in Disability Policy, contributed to this report.

For assistance with legal issues on this topic contact (name redacted), Legislative Attorney, or Jennifer Staman, Legislative Attorney.
The Congressional Research Service (CRS) is a federal legislative branch agency, housed inside the Library of Congress, charged with providing the United States Congress non-partisan advice on issues that may come before Congress.

EveryCRSReport.com republishes CRS reports that are available to all Congressional staff. The reports are not classified, and Members of Congress routinely make individual reports available to the public.

Prior to our republication, we redacted names, phone numbers and email addresses of analysts who produced the reports. We also added this page to the report. We have not intentionally made any other changes to any report published on EveryCRSReport.com.

CRS reports, as a work of the United States government, are not subject to copyright protection in the United States. Any CRS report may be reproduced and distributed in its entirety without permission from CRS. However, as a CRS report may include copyrighted images or material from a third party, you may need to obtain permission of the copyright holder if you wish to copy or otherwise use copyrighted material.

Information in a CRS report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to members of Congress in connection with CRS’ institutional role.

EveryCRSReport.com is not a government website and is not affiliated with CRS. We do not claim copyright on any CRS report we have republished.